Expression of recombinant proteins in Trichoplusia ni pupae
By employing Trichoplusia ni pupae infected with recombinant AcMNPV and enhanced transcriptional regulators, the method addresses inefficiencies in protein production, achieving high yields and cost reductions through automation and scalability.
Patent Information
- Application Number
- JP2023064436
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2015-09-17
- Filing Date
- 2023-04-11
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2036-09-19
AI Technical Summary
Current methods for producing recombinant proteins in insect cells, particularly in Trichoplusia ni pupae, face inefficiencies due to low expression yields, labor-intensive manual processes, and difficulties in automation, leading to scalability and cost issues.
Utilizing Trichoplusia ni pupae infected with a recombinant Autographa californica multicapsid nuclear polyhedrosis virus (AcMNPV) and enhanced transcriptional regulators (IE-1 and IE-0) to increase protein expression beyond endogenous levels, combined with automated processes for inoculation and silk removal, enabling scalable and efficient protein production.
The method achieves significantly higher recombinant protein yields, reduces production costs by up to 90%, and facilitates automation, making it a more efficient and cost-effective system for industrial-scale protein production.
Smart Images

Figure 0007595371000002 
Figure 0007595371000003 
Figure 0007595371000004
Abstract
Description
[Technical field]
[0001] The present invention can be included in the field of biotechnology and in particular in the field of insects. Recombinant transcription factors in insect pupae, especially those of Trichoplusia ni (T. ni) For the industrial production of proteins, the efficiency of recombinant protein expression is increased. Furthermore, the present invention encompasses means and methods for optimizing the production of baculovirus. The pupae themselves, which contain , transduced or transfected pupae. [Background technology]
[0002] Baculovirus expression vector systems (BEVS) are used to express recombinant proteins, e.g., vaccines. Established methods for the production of proteins to be used as therapeutic molecules or diagnostic reagents Due to its overexpression potential and rapid development, BEVS is an ideal candidate for recombinant vectors of any interest. Recombinant protein expression is one of the most attractive options for the production of recombinant proteins. The baculovirus vectors most widely used in the industry use Spodoptera as the preferred expression host. Spodoptera frugiperda 9 (Sf9) or 21 (Sf21) insect Autographa californica nuclear polyhedrosis virus (APC) in human cells AcMNPV) (Non-Patent Document 1), and Insect larvae of Trichoplusia ni (T. ni) as biofactories (Non-patent literature 2) Since the development of BEVS in the 1980s (Non-Patent Document 3), In virus-infected insect cells, hundreds of proteins ranging from cytosolic enzymes to membrane-bound proteins are expressed. have been successful in producing recombinant proteins.
[0003] Recently, new baculovirus vectors have been described. Reference 2 describes recombinant DNA vectors for the expression of recombinant proteins in insects and insect cells. The elements are described.
[0004] A process for converting a low-value substrate, mulberry leaves, into a high-value protein-based product, silk Approximately 70,000 tons of silk are produced worldwide each year. Insects have an accelerated metabolism, which makes them very Bombyx mori (B. mori, Ca Lepidoptera such as T. iko (cabbage looper) or T. ni (cabbage looper) are bio- These are two of the most commonly used insects in botany. They live for about 2 weeks. They increase in size by 5,000 times, producing over a kilometre of silk per B. mori insect. Silk gland-derived cells can produce approximately 80 μg of protein per cell per day. In contrast, the best mammalian cell culture systems produce only about 50 pg of protein per cell per day. It only produces proteins.
[0005] Therefore, insects as living biofactories have the potential to be versatile, scalable, and automatable. Due to their potential, efficiency and speed of development, they are more widely used than insect cells, traditional fermentation techniques and plant-derived proteins. For example, insects as living biofactories constitute a promising alternative to For example, this avoids the need for bioreactors for protein expression in insect cells. Oreactors are inefficient, expensive, and technically complex (taking years to build and validate). They are difficult to operate, require highly skilled individuals to operate, are prone to contamination, and are unreliable. Therefore, there are technical and economical options for the production of new and existing recombinant proteins. Moreover, bioreactors face the problem of limited scalability.
[0006] B. mori larvae express recombinant proteins using a baculovirus expression vector system. It is currently widely used as a living biofactory (Non-Patent Document 4, Non-Patent Document 5). , Non-Patent Document 6, Non-Patent Document 7, Non-Patent Document 8, Non-Patent Document 9).
[0007] T. ni larvae are also used to express recombinant proteins (Non-Patent Document 10, Non-Patent Document 20, Patent Document 2, Non-Patent Document 11, Non-Patent Document 12, Non-Patent Document 13, Non-Patent Document 14, Non-Patent Document Reference 15, Non-Patent Reference 16, Non-Patent Reference 17).
[0008] In silkworms, comparative studies have shown that for most proteins, the highest levels are observed in the larvae instead of the pupae. It was demonstrated that high expression yields were obtained (Non-Patent Document 18, Non-Patent Document 19). Reference 19). In addition, the effect of pupae on baculovirus infection in silkworms was also examined in relation to their age. A decrease in the sensitivity of larvae to the microbial activity of the fungus was reported (Non-Patent Document 20). For this reason, infection with baculovirus is generally performed orally instead of by inoculation (injection). Since the virus cannot be transmitted orally, it must be injected manually, a lengthy and laborious process. In addition, silkworm pupae generally undergo a lengthy process before inoculation with the virus occurs. They are covered in a thick cocoon that must be removed by hand using a cess.
[0009] Due to the lower protein expression yield in common silkworm pupae and the difficulty of its manipulation, The use of larvae for the production of recombinant proteins has become universally favored.
[0010] Similar disadvantages have been observed in other systems, such as Hyalophora cecropia pupae. The expression of certain proteins in H. cecropia pupae is lower than that in T. niger larvae. Furthermore, Hyalophora cecropia moths are difficult to rear and require strict They are univoltine (one generation per year), produce very few eggs per cycle, and produce high amounts of cocoons. The density is high (thick cocoons must be removed (manually) before inoculation with the virus, All these disadvantages make recombinant protein expression a difficult proposition. Therefore, we have used Hyalophora cecropia pupae as a poorly adapted system, especially for the expression of recombinant proteins. This results in a system that is poor in efficiency, scalability and automation.
[0011] For the expression of recombinant proteins in insects using BEVS, specifically To develop a more efficient, easily automated system for the industrial expression of recombinant proteins in insects. There is a demand to scale up.
[0012] After extensive research, the inventors have discovered a solution to the above problem, namely, the development of a more efficient larval insect species belonging to the order Lepidoptera. More preferably, expression in pupae of Trichoplusia ni species is more efficient than expression in larvae, Furthermore, it allows for almost complete automation (scale-up), increasing efficiency, especially on an industrial scale. A protein expression system has been discovered that reduces the costs associated with expressing recombinant proteins. [Prior art documents] [Chartered documents]
[0013]
Patent Document 1
Patent document 2
Non-licensed literature
[0014] [Non-licensed document 1] Nettleship, JE, Assenberg, R., Diprose, JM, Rahman-Huq, N., Owens, RJ Recent advances in the production of proteins in insect and mammalian cells for structural biology. J. Struct. Biol. 2010, 172, 55-65
Non-licensed Document 2
Non-licensed Document 4
Wood 5
Wood 6
Waterfall 7
Outdoor Track 8
Outdoor Tools9
Outdoor Tools 10
Outdoor Content11
Outdoor Tools 12
Outdoor Content13
Outdoor Tools 14
Outdoor Tools 15
Outdoor Content 16
Outdoor Track 17
Outdoor Tools 18
Non-Patent Document 19
Non-Patent Document 20
Non-Patent Document 21
Summary of the Invention
Problems to be Solved by the Invention
[0015] Thus, the present invention provides recombinant proteins for use in diagnostics, vaccines and therapeutic treatments. Autographa californica multicapsid nuclear polyhedrosis virus (MPV) is used to produce IgG proteins. (Autographa californica multicapsid nucleopolyhedrovirus) (AcMNPV) A baculovirus vector derived from a lepidopteran parasite, more preferably a lepidopteran parasite, The use of pupae (chrysalises) belonging to the species Lycoplusia ni. Use of pupae derived from Trichoplusia ni species for protein expression, especially recombinant Industrial Use of Pupae Derived from Trichoplusia ni Species for Protein Expression This has not yet been reported. [Means for solving the problem]
[0016] The present invention relates to Autographa californica multicapsid nuclear polyhedrosis virus (APC). Recombinant baculovirus and / or transfer vectors / transfer vectors derived from MNPV Provide pupae containing cumids.
[0017] Furthermore, the present invention provides a method for the regulation of transcription above endogenous levels obtained during baculovirus infection. Protein IE-1, protein IE-0 and / or their fragments that function as node factors A nucleic acid sequence that allows for expression of a gene fragment at above endogenous levels and expression of a recombinant protein. The recombinant homology region ( hr) and providing a pupa containing the same.
[0018] The present invention also relates to the use of the pupae of the invention for the expression of recombinant proteins.
[0019] Furthermore, the present invention relates to a method for producing a (a) preparing pupae; (b) Autographa californica multicapsid nuclear polyhedrosis virus (AcMN PV) into the pupae of step (a); (c) carrying out the steps (a) and (b) for a period of time sufficient to express at least one recombinant protein. b) incubating the inoculated pupae; (d) obtaining pupae containing at least one recombinant protein; (e) optionally harvesting the at least one recombinant protein; (f) optionally purifying at least one recombinant protein; The present invention provides a method for producing at least one recombinant protein, comprising:
[0020] Further, the present specification provides: (a) providing pupae contained in cocoons; (b) preferably by means of a specially designed apparatus, subjecting the pupae contained within the cocoons to a salt of hypochlorite, preferably Preferably, treating with a solution of sodium hypochlorite; (c) obtaining silk-free (and optionally essentially externally sterilized) pupae; The present invention can be automated to reduce the operations for producing silk-free pupae belonging to the order Lepidoptera, including A method is provided.
[0021] A method for producing a recombinant baculovirus comprising: (a) preparing pupae; (b) Autographa californica multicapsid nuclear polyhedrosis virus (AcMN Transfer vectors suitable for producing recombinant baculovirus derived from transfecting the pupae of step (a) with a bacmid; (c) inoculating the culture medium of step (b) for a period of time sufficient to produce a recombinant baculovirus. Incubating the exposed pupae; (d) obtaining pupae containing the recombinant baculovirus; (e) optionally harvesting the recombinant baculovirus; (f) optionally purifying the recombinant baculovirus; Includes.
[0022] The present invention also relates to a precision pump, a mobile mechanical arm and a method for detecting Lepidoptera, preferably Trichoptera. Genus Trichoplusia, Rachiplusia, Spodoptera a) Genus Heliothis, Manduca, Helicoverpa pa), Ascalapha, or Samia, more preferably Trichomonas. Prusia, Lachypursia, Spodoptera, Heliothis, or Helicoverpa, etc. More preferably, Trichoplusia ni species, Rachiplusia nu plusia nu), Spodoptera frugiperda, Heliothis Heliothis virescens species, Helicoverpa armigera armigera species, Helicoverpa Zea species, Mandsuka sexta species uca sexta species, Ascalapha odorata species, or Samia synthia A movable needle (or needles) suitable for injecting fluid into pupae belonging to the species Samia cynthia. In some cases, the present invention relates to an apparatus comprising: [Brief description of the drawings]
[0023] [Figure 1] FIG. 1 is a diagram of the large-scale disposable T. ni insect rearing module. FIG. 2 is a diagram of 5th instar larvae developing in the insect rearing module. [Diagram 2] Comparison of cocoons (left part of the image) and silk-free pupae (right part of the image) formed by Bombyx mori and Trichoplusia diversifolia. [Diagram 3] A semi-automatic device for the removal of silk from T. ni cocoons. A schematic of the machine with two containers and one mechanical arm in which the disposable rearing modules are placed. The first container contains hypochlorous acid and a system for releasing liquid through the rearing module containing the cocoons, which helps to dissolve more efficiently the silk surrounding the pupae. The second container is for washing the pupae, which sprays them with water. In the lid of this container there is a system for providing air to dry the pupae. At the end of the process the pupae are silk-free and ready to be used for infection or to be stored refrigerated until use. [Figure 4] 1 is a diagram of a baculovirus expression cassette used for the production of green fluorescent protein (GFP). A) A diagram of a conventional baculovirus expression cassette using the polyhedrin promoter (e.g., SEQ ID NO: 23). B) A diagram of a TB expression cassette comprising the Ac-ie-01 cDNA encoding the transactivators IE1 and IE0 expressed under the control of the polyhedrin promoter; the enhancer sequence hr1 driving the expression of GFP and the chimeric promoter p6.9-p10 (e.g., SEQ ID NO: 17 and a nucleic acid sequence encoding GPF, e.g., SEQ ID NO: 38). [Diagram 5]Diagram of automated inoculation of T. ni pupae by a robot that injects recombinant baculovirus. A) Schematic of the inoculation robot. B) Schematic of the matrix of pits in which insect pupae are placed. These pits containing the pupae have perforated lids and are stackable, facilitating transport of the pupae to the production laboratory and being compatible with the inoculation robot. In the same panel, actual photographic images of the pits containing the pupae and with their lids are shown. C) Schematic of inoculation of pupae by a needle connected to a robotic arm. [Figure 6] Comparative analysis of GFP protein expression yields in infected pupae by using conventional baculovirus TB(-) (polyhedrin promoter, e.g. SEQ ID NO: 23) or TB modified baculovirus TB(+). A) Coomassie blue stained SDS-PAGE separating protein extracts from pupae infected with TB(-) or TB(+) baculoviruses. (-) corresponds to extracts from uninfected control pupae. B) Quantification of GFP production yields obtained in pupae infected with each analyzed baculovirus, expressed in mg per g pupal biomass. [Figure 7] Diagram of baculovirus expression cassettes used to produce capsid protein (Cap) from porcine circovirus type 2 (e.g., SEQ ID NO: 26) or hemagglutinin (HA) from influenza virus (e.g., SEQ ID NO: 30). A) Diagram of a conventional baculovirus expression cassette using the polyhedrin promoter. B) Diagram of a TB expression cassette comprising the cDNA of Ac-ie-01 encoding the transactivators IE1 and IE0 expressed under the control of the polyhedrin promoter; enhancer sequence hr1 and chimeric promoter p6.9-p10 driving expression of the above mentioned proteins. [Figure 8]Comparative analysis of Cap protein (e.g. SEQ ID NO: 26) expression yields in infected pupae by using conventional baculovirus TB(-) (polyhedrin promoter, SEQ ID NO: 10, SEQ ID NO: 28), or TB modified baculovirus TB(+) (e.g. SEQ ID NO: 27 or SEQ ID NO: 29). A) Coomassie blue stained SDS-PAGE separating protein extracts from pupae infected with TB(-) or TB(+) baculoviruses. (-) corresponds to extracts from uninfected control pupae. B) Quantification of Cap production yields obtained with pupae infected with each analyzed baculovirus, expressed in mg per g pupal biomass. [Figure 9] Comparative analysis of expression yields of HA protein (SEQ ID NO: 30) in infected pupae by using conventional baculovirus TB(-) (polyhedrin promoter, SEQ ID NO: 10) or TB modified baculovirus TB(+) (e.g. SEQ ID NO: 31). A) Coomassie blue stained SDS-PAGE separating protein extracts from pupae infected with TB(-) or TB(+) baculoviruses. (-) corresponds to extracts from uninfected control pupae. B) Quantification of HA production yields obtained with pupae infected with each baculovirus analyzed, expressed in mg per g pupal biomass. [Figure 10] FIG. 1 is a diagram of the baculovirus expression cassettes used to produce GFP, Cap (SEQ ID NO: 26), HA (SEQ ID NO: 30), and VP60 proteins from rabbit hemorrhagic disease virus (RHDV, SEQ ID NO: 32 or SEQ ID NO: 33) in T. ni larvae and pupae. FIG. 2 is a schematic representation of the TB expression cassette comprising the Ac-ie-01 cDNA encoding the transactivators IE1 and IE0 expressed under the control of the polyhedrin promoter; the enhancer sequence hr1 and the chimeric promoter p6.9-p10 driving the expression of the above mentioned proteins. [Figure 11]Comparative analysis of GFP protein expression yields in infected pupae and larvae. A) Coomassie blue stained SDS-PAGE separating protein extracts from TB(+) baculovirus infected pupae (P) or infected larvae (L). (-) corresponds to extracts from uninfected control pupae. B) Quantification of GFP production yields obtained in infected pupae or larvae, expressed in mg per g insect biomass. [Figure 12] Comparative analysis of Cap protein expression yields in infected pupae and larvae. A) Coomassie blue stained SDS-PAGE separating protein extracts from TB(+) baculovirus infected pupae (P) or infected larvae (L). (-) corresponds to extracts from uninfected control pupae. B) Quantification of Cap production yields obtained in infected pupae or larvae, expressed in mg per g insect biomass. [Figure 13] Comparative analysis of HA protein expression yields in infected pupae and larvae. A) Coomassie blue stained SDS-PAGE separating protein extracts from TB(+) baculovirus infected pupae (P) or infected larvae (L). (-) corresponds to extracts from uninfected control pupae. B) Quantification of HA production yields obtained in infected pupae or larvae, expressed in mg per g insect biomass. [Figure 14] Comparative analysis of expression yields of RHDV capsid VP60 protein (G1 and RHDVb) in infected pupae and larvae. A) Coomassie blue staining of SDS-PAGE separating protein extracts from pupae (P) or infected larvae (L) infected with TB(+) baculovirus. (-) corresponds to extracts from uninfected control pupae. B) Quantification of RHDV capsid protein production yields obtained with infected pupae or larvae, expressed in mg per g insect biomass (L) with TB(+) baculovirus. (-) corresponds to extracts from uninfected control pupae. B) Quantification of RHDV capsid protein production yields obtained with infected pupae or larvae, expressed in mg per g insect biomass. [Figure 15] Figure 1. Diagram of VLPs formed after infection of T. ni pupae with TB(+) baculoviruses expressing VP60 proteins derived from RHDV G1 and RHDVb. Extracts from pupae infected with each baculovirus at optimal production time were processed for VLP purification. Samples were observed by electron microscopy using negative staining. The figure shows VLPs at two magnifications. VLPs obtained with the two baculoviruses presented identical size and shape. Micrographs are representative of the analyzed fields. [Figure 16] FIG. 1 shows a schematic example of a procedure for obtaining viral inoculum from infected pupae in the absence of insect cell culture. [Figure 17] Schematic example of upstream and downstream processing procedures to obtain purified recombinant protein from infected pupae in three steps. A) Schematic of production of T. ni pupae, their manipulation and optional transport to final destination (e.g. pharmaceutical company) for recombinant protein production. B) Schematic of storage of pupae, robotic inoculation with recombinant baculovirus using the device of the invention, incubation and freezing of insect biomass, which can be stored for several months before processing in situ or easily transported to other locations for further downstream processing. C) Schematic of downstream processing of frozen biomass by conventional means, including homogenization, tangential flow filtration and protein purification. [Figure 18] FIG. 10 shows a comparison of expression yields of porcine circovirus Cap protein in insect cells by using conventional baculovirus and TopBac-modified baculovirus in insect cells and insect pupae. [Figure 19] FIG. 1 is a schematic example of a procedure for obtaining a viral inoculum from infected pupae. [Figure 20] FIG. 14. Schematic example of downstream processing steps to obtain purified recombinant protein from infected pupae. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] definition As used herein, "pupa" refers to the life stage of certain insects undergoing metamorphosis. is found in insects that undergo complete metamorphosis (holometabolous insects). These insects have embryo, larva, pupa, and and adult. The pupa of a butterfly is also called a chrysalis. Insects are The pupa may be protected by being enclosed in a cocoon, a protective silk casing that forms the pupae of many insects.
[0025] As used herein, "baculovirus" refers to an infectious virus for invertebrates. The term "recombinant baculovirus" refers to the family of viruses that mainly infect insects and arthropods. has further recombinant DNA introduced, for example, through homologous recombination or transposition. The recombinant baculovirus expresses Autographa californica multicapsid nuclear polyhedra. The pathogenic virus may be derived from the pathogenic virus (AcMNPV).
[0026] As used herein, an "expression cassette" refers to a gene itself and / or a vector that controls the expression of this gene. Recombination involving the expression of specific genes, such as regulatory elements (e.g., promoters) For example, an expression cassette useful in the present invention may include the following recombinant DNA element: Contains DNA elements. 1. Allows expression of recombinant proteins, such as those described herein below and preferably a nucleic acid sequence controlling its expression (at least a promoter ),and, 2. Normal expression of the above regulatory factors obtained during baculovirus infection of insect cells or insects; That is, baculovirus transcriptional regulators such as IE-1 and IE-0 exceed endogenous levels. A nucleic acid sequence that allows for the expression of a gene.
[0027] In some embodiments, the expression cassette comprises the sequence encoding a recombinant protein. The enhancer homology region (hr), such as hr1, is operably linked to the promoter of the The recombinant DNA element forming portion of the expression cassette of the present invention is contained in a single nucleic acid molecule. The recombinant DNA element forming portions of the expression cassette may be present in different nucleic acid molecules. Preferably, the different nucleic acid molecules are present in the same cell.
[0028] As used herein, "recombinant DNA" refers to the combination or insertion of one or more DNA strands. Artificial DNA that combines DNA that do not normally occur together by engineering This refers to the form of.
[0029] As used herein, a "recombinant DNA element" includes a promoter, an enhancer, It also refers to a functional element within recombinant DNA, such as a gene.
[0030] As used herein, a "transcriptional regulator" refers to, for example, an enhancer or repressor domain. by binding to the transcription domain and / or recruiting additional proteins involved in transcription. It refers to a regulatory protein that has the ability to regulate the transcription of specific genes. Rice mutant IE-0 is a transcriptional regulator endogenously expressed during baculovirus infection Expression of protein IE-1, protein IE-0 and / or fragments thereof The current level can be determined by any method known to those skilled in the art, such as quantitative PCR or Western blot analysis. The method can be specific at both the mRNA and protein levels.
[0031] According to the present invention, IE-1, IE-0 and / or fragments thereof are These proteins were then used to increase the total levels of these proteins above endogenous levels during viral infection. This can be achieved by, for example, introducing additional copies of the endogenous gene, Alternatively, this can be achieved by manipulating the expression of the endogenous gene's promoter. Additional copies of the gene are inserted into the vector under the control of a suitable promoter, such as polh or pB29. It can be introduced as a gene.
[0032] IE-1, IE-0 and their fragments are represented by SEQ ID NO: 1 (also Ac-ie-01). SEQ ID NO: 1 can be encoded by the nucleic acid of IE-1 and I SEQ ID NO:2 is the cDNA of Ac-ie-01, which encodes both IE-1 and IE-0. SEQ ID NO: 4 and SEQ ID NO: 5 are the coding sequences (CDS) of IE-0. Column number 5 shows the N-terminal domains of IE-1 and IE-0, respectively, that retain catalytic transcriptional regulatory activity. The proteins encoded by SEQ ID NO:2 to SEQ ID NO:5 are They are represented by SEQ ID NO:6 to SEQ ID NO:9, respectively.
[0033] The nucleic acid and amino acid sequences referred to in this invention are each encoded by E Identified using the MBOSS Needle (http: / / www.ebi.ac.uk / Tools / psa / emb oss_needle / ) to identify other nucleic acid sequences and amino acids according to their degree of sequence identity or sequence similarity. Methods for generating such variants include random mutagenesis. site-directed mutagenesis, site-saturation mutagenesis, PCR-based fragment amplification Swertia bristletrix, DNA shuffling, in vitro or in vivo homologous recombination and gene synthesis methods.
[0034] As used herein, a "variant" refers to a mutant whose nucleic acid or amino acid sequence differs from that of a parent nucleic acid or amino acid sequence. A nucleic acid or amino acid sequence that differs from the sequence of the corresponding amino acid at one or more positions, the difference being the nucleic acid or amino acid There may be additions, deletions and / or substitutions of residues.
[0035] As used herein, "homology regions" (hr) refer to the incomplete 30 bp region near their centers. The homologous region is composed of approximately 70 bp repeat units with a palindrome. It is repeated at eight locations in the AcMNPV genome with 2 to 8 flanking repeats. The homologous region acts both as a transcription enhancer and as an origin of baculovirus DNA replication. can be done.
[0036] As used herein, an "enhancer region" refers to a region that is associated with a transcriptional regulatory factor by binding thereto. It refers to a regulatory sequence that increases the transcription level of an associated gene.
[0037] As used herein, a "recombinant protein" refers to a protein that is produced from recombinant DNA. Such proteins can be used for the benefit of humans and animals and are of industrial use. It may have commercial or therapeutic applications.
[0038] As used herein, "operably linked" refers to the ability of one to regulate the other, e.g., in terms of transcriptional regulation. It refers to two nucleic acid sequences that are linked together in such a way that they affect each other.
[0039] As used herein, a "promoter" refers to a gene that initiates transcription upon binding of RNA polymerase. The term refers to a DNA sequence that can initiate transcription. The sequence includes a transcription factor or other transcription regulating molecule. The promoter sequence may further comprise a DNA sequence Various promoter fragments (different or identical fragments) closely localized in or a combination of the two) separated by a linker or spacer. Such a promoter is called a chimeric promoter.
[0040] As used herein, a "transfer vector" refers to a vector that is inserted into the baculovirus genome. Vectors (i.e. vehicles for carrying genetic material) that allow the insertion of genetic information DNA molecules used as vectors.
[0041] As used herein, a "bacmid" refers to a vector that, when transfected into a cell or insect, Refers to a plasmid construct that contains sufficient DNA sequences to generate a baculovirus.
[0042] As used herein, a "cloning vector" refers to any vector suitable for cloning. A vector that contains a restriction site, an origin of replication for bacterial propagation, and a selectable marker. .
[0043] The cloning vectors that can be used in the present invention include: (i) protein IE-0; The present invention relates to sequences for expression of IE-1 and / or fragments thereof above endogenous levels. and (iii) linked to a suitable promoter to drive expression of the recombinant protein. Preferably, the recombinant homology region (hr) is included in the (ii) region. A vector may contain a nucleic acid sequence that encodes a recombinant protein (i.e., A cloning vector containing the expression cassette (also called a "donor vector"). Generally, the cloning vector lacks such sequences.
[0044] As used herein, a "vaccine" preferably refers to an active acquired defense against a particular disease. It may be defined as a biological product that contains a recombinant protein that provides immunity.
[0045] As used herein, the term "about" means ±1% of the stated value of the value, or "about The term "about" means ±2% of the stated value, or the term "about" means ±5% of the stated value. The term "about" means ±10% of the stated value, or the term "about" means ±10% of the stated value. The term "about" means ±20% of the stated value, or the term "about" means ±30% of the stated value. Preferably, the term "about" means exactly the stated value (±0%).
[0046] Detailed Description The present invention relates to recombinant baculoviruses and / or transfer vectors / bacmids. The present invention surprisingly provides a recombinant baculovirus, particularly an endogenous recombinant baculovirus, which is capable of expressing an endogenous gene. Introduction of sequences that induce expression of baculovirus transcriptional regulators beyond the bell into insect pupae, and optionally an enhancer homology region (hr) sequence, a promoter or a combination of promoters. The introduction of these combinations can increase recombinant protein production to unprecedented levels. This demonstrates the potential of recombinant proteins in vivo, particularly in We demonstrate the utility of this system for the industrial production of recombinant proteins in vivo.
[0047] The pupa of the present invention The present invention relates to recombinant baculoviruses and / or transfer vectors and / or Providing pupae containing the bacmid. Recombinant baculovirus and / or transferase Vectors and / or bacmids are used to express Autographa californica multicapsid nucleoproteins The pupae are preferably derived from the keratinocyte virus (AcMNPV). Trichoplusia, Lachyplusia, Spodoptera, Heliothis, Manduca, Heli Coberpa, Ascara, or Samia, preferably Trichoplusia, Lakkiplusia A species of the genus Acanthurus, Spodoptera, Heliothis, or Helicoverpa, more preferably Trichople Scia ni sp., Lachypurusia nu sp., Spodoptera frugiperda sp., Heliothis virgatus Helicoverpa armigera species, Helicoverpa gii species, Manzuca sexta Preferably, the pupae belong to the species Ascalapha odorata or Samia cynthia. More preferably, the species belongs to Trichoplusia ni. The pupa of the present invention does not belong to the species Bombyx mori. Not belonging to the species Vora cecropia.
[0048] In a preferred embodiment, the pupa of the present invention is Autographa californica multicapsule. Recombinant baculovirus derived from AcMNPV and / or Trichoplusia sp., preferably Trichoplusia , containing the transfer vector / bacmid This is a pupa belonging to the A-Ni species.
[0049] The pupae of the present invention, in particular T. ni pupae, can be transformed, particularly in an automated and scalable process. This provides several advantages for the expression of mitochondrial proteins. For example, a pair of T. nigricans moths can express 1 In addition, the eggs produced by the pupae of T. ni may be approximately 1000 eggs per cycle. The cocoons are the pupae of other species (e.g. Bombyx mori or Hyalophora cecropia). This makes it possible to automate and scale the production process (e.g., by using recombinant proteins) The pupae of T. ni are particularly suitable for use in the industrial production of lactic acid bacteria. or Autographa californica multicapsid nuclear polyhedrosis virus (AcMNP V) recombinant baculovirus and / or transfer vector derived therefrom, and / or or bacmid-infected T. niger pupae are efficient and scalable for recombinant protein production A further advantage of this system is its high productivity (by The technology is technically simple and easy to implement and verify. In fact, cost savings (>90% reduction in fixed capital investment for bioreactor use), Low-cost product, short generation time (baculovirus system), high efficiency for difficult-to-produce proteins as well as high quality and safety of the products produced.
[0050] The inventors of the present application have surprisingly found that pupae, in particular of the order Lepidoptera, preferably of the genus Trichoplusia, Lachypurusia, Spodoptera, Heliothis, Manduca, Helicoverpa, Asca Rapha or Samia, preferably Trichoplusia, Lachyplusia, Spodoptera genus, Heliothis, or Helicoverpa, more preferably Trichoplusia ni, Laquip Lucia nus species, Spodoptera frugiperda species, Heliothis virescens species, Helico Verpa armigera species, Helicoverpa zee species, Manduca sexta species, Ascarafa Expression of recombinant proteins in pupae belonging to the species Odorata or Samia synthia was observed in larvae. Expression was found to be comparable to, and even higher than, that in worms.
[0051] The patent application published as US Pat. No. 5,999,633 describes recombinant baculoviruses that may be contained in the pupae of the present invention. The viruses and transfer vectors and bacmids are disclosed.
[0052] The recombinant baculovirus and / or transfer vector contained in the pupa according to the present invention Preferably, the vector and / or bacmid may comprise recombinant DNA. Recombinant baculovirus and / or transfer vector contained in pupae by The bacmid and / or the recombinant protein comprises a nucleic acid sequence encoding the recombinant protein. The vaccines are available as subunit monomer vaccines, subunit multimer vaccines, and virus-like particles. , therapeutic proteins, antibodies, enzymes, cytokines, blood clotting factors, anticoagulants, receptors, a fluorescent protein, a diagnostic protein reagent, and a green fluorescent protein (GFP) and / or the recombinant protein is preferably Preferably, the protein is not a protein endogenously produced by the pupa. Recombinant baculovirus and / or transfer vector contained in the pupae, Or the bacmid may express transcriptional regulators above the endogenous levels obtained during baculovirus infection. The protein IE-1, the protein IE-0, and / or their flags functioning as children The nucleic acid sequence includes a nucleic acid sequence that allows for expression of a marker above endogenous levels (e.g., The expression of more than 1000 ng / ml of the IE-1 protein, the IE-2 protein, and the IE-3 protein in recombinant baculoviruses was Additional copies of nucleic acid sequences allowing expression of IE-0 and / or fragments thereof The recombinant baculovirus contained in the pupae according to the present invention can be obtained by the presence of The vector and / or transfer vector and / or bacmid are used to express recombinant proteins. The recombinant homology region operably linked to any promoter suitable for driving expression. It is preferred that it further contains (hr).
[0053] The transfer vector that may be contained in the pupa of the present invention is: (i) protein IE-0, for expression of protein IE-1 and / or fragments thereof above endogenous levels. In addition to the sequence, (iii) a promoter suitable for driving expression of the recombinant protein. Preferably, the recombinant gene comprises (ii) a recombinant homology region (hr) linked to the In the present invention, the transfer vector contains a nucleic acid sequence encoding the recombinant protein. In another preferred embodiment, the transfer vector lacks such sequences. In an embodiment, the transfer vector is a bacmid.
[0054] Transfer vectors and / or bacmids are commercially available baculoviruses. The expression systems "Bac-to-Bac™" (Invitrogen™), "BacPA K (trademark)" (Clontech (trademark)), "FlashBAC (trademark)" (Oxford Expressio n Technologies (trademark)), "BacuVance (trademark)" (GenScript (trademark)), “Bac-N-Blue DNA (trademark)” (invitrogen (trademark)), “BaculoD irect (trademark)” (invitrogen (trademark)), “BacVector (trademark)” 100 0, 2000, 3000 (Novagen (trademark)), “DiamondBac (trademark)” (Sig ma-Aldrich™), or "BaculoGold™" (BD biosciences™) )) may be derived from either
[0055] The pupa of the present invention (preferably Lepidoptera, preferably Trichoplusia, Lachypurusia, Sporoplusia, Doptera, Heliothis, Manduca, Helicoverpa, Ascarapha, or Sa Mia, preferably Trichoplusia, Lachyplusia, Spodoptera, Heliothis , or Helicoverpa genus, more preferably Trichoplusia ni species, Lachyplusia nu species , Spodoptera frugiperda species, Heliothis virescens species, Helicoverpa al. Miguela species, Helicoverpa zee species, Manzuca sexta species, Ascala odorata species, or Samia cynthia species, or other lepidoptera susceptible to AcMNPV infection, more preferably Preferably, the genus Trichoplusia and the species Trichoplusia ni are baculoviruses Proteins IE- that function as transcriptional regulators above endogenous levels obtained during infection 1. Expression of protein IE-0 and / or fragments thereof above endogenous levels The recombinant DNA elements described above may comprise nucleic acid sequences that enable Preferably, the vector is introduced into the pupae by recombinant baculovirus.
[0056] The present invention provides a method for the production of baculovirus infections that can be used to increase the expression of transcriptional regulators at levels greater than endogenous levels obtained during baculovirus infection. Protein IE-1, protein IE-0 and / or fragments thereof functioning as The nucleic acid sequence enabling expression of the (a) a nucleic acid comprising a nucleotide sequence shown in any one of SEQ ID NOs: 1 to 5; (b) a nucleotide sequence having at least 7 parts by weight, 0%, preferably at least 75%, more preferably at least 80%, more preferably At least 85%, more preferably at least 90%, and most preferably at least 9 It has 5% sequence identity with baculovirus and functions as a transcriptional regulator in recombinant baculovirus. a nucleic acid sequence encoding a protein to be obtained; (c) a coding sequence including an amino acid sequence shown in any one of SEQ ID NO:6 to SEQ ID NO:9; A nucleic acid sequence for coding the nucleic acid sequence, (d) a sequence that is at least 70% identical to any one of the amino acid sequences shown in SEQ ID NO:6 to SEQ ID NO:9; , preferably at least 75%, more preferably at least 80%, more preferably at least at least 85%, more preferably at least 90%, and most preferably at least 95% and can function as a transcriptional regulator in recombinant baculoviruses. A nucleic acid sequence encoding an amino acid sequence, It is preferably selected from the group consisting of:
[0057] The sequences of the mutants of SEQ ID NO:1 to SEQ ID NO:5 are slightly different from the sequences of SEQ ID NO:1 to SEQ ID NO:5. At least 70%, preferably at least 75%, more preferably at least 80%, Preferably at least 85%, more preferably at least 90%, and most preferably at least are at least 95% identical.
[0058] The sequences of the mutants of SEQ ID NO:6 to SEQ ID NO:9 are slightly different from the sequences of SEQ ID NO:6 to SEQ ID NO:9. At least 70%, preferably at least 75%, more preferably at least 80%, Preferably at least 85%, more preferably at least 90%, and most preferably at least At least 95% similar.
[0059] The pupae of the present invention can be transfected with any promoter suitable for driving the expression of a recombinant protein. The nucleic acid sequence and / or the recombinant gene further comprises an operably linked recombinant homology region (hr). The recombinant baculovirus and / or transfer vector and / or bacmid may be further It may include.
[0060] The recombinant homologous region (hr) is preferably the sequence shown in SEQ ID NO: 21 (hr1). I wish.
[0061] The promoter driving the expression of the recombinant protein is (a) a compound represented by any one of SEQ ID NOs: 10 to 14, preferably SEQ ID NOs: 11 to 14 A nucleic acid comprising a nucleotide sequence as set forth in any of SEQ ID NOs: 13, and (b) a sequence capable of functioning as a promoter in a recombinant baculovirus; The sequence shown in any one of SEQ ID NO: 10 to SEQ ID NO: 14, preferably SEQ ID NO: 11 to SEQ ID NO: 1 3, which has at least 70%, preferably at least 7 5%, more preferably at least 80%, more preferably at least 85%, more preferably or at least 90%, and most preferably at least 95% sequence identity to array, It is preferred that the nucleic acid is selected from the group of nucleic acids comprising:
[0062] In a preferred embodiment, a recombinant promoter, a sequence encoding a transcriptional regulator, and A nucleic acid sequence including a combination with an enhancer region (a nucleic acid sequence included in the pupa of the present invention) Selected from the group consisting of SEQ ID NO:15 to SEQ ID NO:20.
[0063] The recombinant promoter, the sequence encoding the transcriptional regulator, and the enhancer region of the present invention The regions do not necessarily form part of a single molecule; instead, these sequences may be As long as they are operably linked, i.e., contained within the same cell within the pupa, the expression of different molecules can be It may form a part.
[0064] The pupa of the present invention, and / or the recombinant baculovirus and / or the transfer vector The vector and / or bacmid may further comprise a nucleic acid sequence encoding a recombinant protein. The nucleic acid sequence may be a nucleic acid sequence encoding the protein IE-1, the protein IE-0, and / or their fragments. A nucleic acid sequence that allows for expression above endogenous levels of the fragment, and optionally a homology region (h r), the sequences of which are as described above. .
[0065] Recombinant proteins are available as subunit monomer vaccines, subunit multimer vaccines, Virus-like particles, therapeutic proteins, antibodies, enzymes, cytokines, blood clotting factors, anticoagulants From drugs, receptors, hormones, diagnostic protein reagents, and green fluorescent protein (GFP) It is preferably selected from the group consisting of:
[0066] In a preferred embodiment, the recombinant protein is a virus-like particle protein, preferably or selected from the group consisting of: (a) a capsid derived from a porcine circovirus, preferably porcine circovirus type 2; Proteins (e.g., SEQ ID NO: 26), (b) foot-and-mouth disease virus VP1 protein, VP3 protein, or VP0 protein; (c) canine parvovirus VP1 and VP2 proteins, (d) porcine parvovirus VP1 protein and VP2 protein, (e) human norovirus (genogroup I or II) capsid protein, (f) calicivirus capsid protein; (g) L derived from a human papillomavirus, preferably human papillomavirus 16 1 protein, (h) hepatitis E protein E2, (i) Infectious bursal disease virus VP1 protein, VP2 protein and V P3 protein, (j) astrovirus ORF2-encoded protein; (k) influenza virus HA protein (e.g., SEQ ID NO: 30), NA protein protein and M1 protein, (l) Hepatitis B core and surface antigens; (m) Rabbit calicivirus, preferably rabbit hemorrhagic disease virus RHDVb and R VP60 protein derived from HDVG1 (e.g., SEQ ID NO: 32 and SEQ ID NO: 33); (n) Human parvovirus VP1 and VP2 proteins.
[0067] For example, the recombinant protein may be:
[0068] A capsid protein derived from a porcine circovirus, preferably porcine circovirus type 2. a nucleic acid represented by the amino acid sequence of SEQ ID NO: 26 or the nucleic acid of SEQ ID NO: 25 It is encoded by the sequence.
[0069] The foot and mouth disease virus (FMDV) VP1, VP3 and VP0 proteins, their sequences are e.g. For example, it may be shown in or derived from the following sequences: -FMDV serotype O complete genome: GenBank JX570650.1 -FMDV serotype A complete genome: GenBank HQ832592.1 -FMDV serotype C complete genome: GenBank AY593810.1 -FMDV serotype SAT1 complete genome: GenBank AY593846.1 -FMDV serotype SAT2 complete genome: GenBank JX014256.1 -FMDV serotype ASIA1 complete genome: GenBank HQ631363.1.
[0070] Canine parvovirus VP1 and VP2 proteins, the sequences of which are shown, for example, in the following sequence: May be indicated or derived from: -Canine parvovirus VP1 gene, partial cds, strain for capsid protein VP1 :1887 / f / 3. GenBank:AB437434.1. -Canine parvovirus VP1 gene, partial cds, strain for capsid protein VP1 :1887 / M / 2. GenBank:AB437433.1. -Canine parvovirus VP2 gene, complete cds, strain: HNI-2-13. GenBank :AB120724.1. -Canine parvovirus VP2 gene, complete cds, strain: HNI-3-4. GenBank: AB120725.1. -Canine parvovirus VP2 gene, complete cds, strain: HNI-3-11. GenBank :AB120726.1. -Canine parvovirus VP2 gene, complete cds, strain: HNI-4-1. GenBank: AB120727.1. -Canine parvovirus VP2 gene, complete cds, strain: HNI-1-18. GenBank :AB120728.1. -Canine parvovirus VP2 protein (VP2) gene, complete cds. GenBank: DQ354068.1. -Canine parvovirus VP2 gene, complete cds, strain: HCM-6. GenBank: AB 120720.1. -Canine parvovirus isolate Taichung VP2 gene, complete cds. GenBan k:AY869724.1. -Canine parvovirus VP2 gene, complete cds, strain: HCM-8. GenBank: AB 120721.1. -Canine parvovirus type 1 proteins VP1 and VP2: GenBank AB5188 83.1 -Canine parvovirus type 2a VP1 and VP2. GenBank: M24003.1 -Canine parvovirus type 2b VP2: GenBank FJ005265.1 -Canine parvovirus type 2C VP2: GenBank FJ005248.1
[0071] Porcine parvovirus VP1 and VP2 proteins, the sequences of which are, for example, May be indicated or derived from: -Porcine parvovirus strain 693a. GenBank: JN400519.1 -Porcine parvovirus strain 8a. GenBank: JN400517.1
[0072] Human parvovirus VP1 and VP2 proteins, the sequences of which are, for example, May be indicated or derived from: -Human parvovirus B19 strain VP1 complete cds. GenBank:AF264149.1 - Human parvovirus B19 isolate Vn115 NS1 (NS1), a 7.5 kDa protein The NS1 protein, VP1 (VP1), 9.5 kDa protein (VP1), and VP2 ( VP2) gene, complete cds. GenBank:DQ357065.1 -B19 virus isolate FoBe VP1 (VP1) and VP2 (VP2) genes, cds. GenBank:AY768535.1 -B19 virus isolate Br543 NS1 (NS1), VP1 (VP1) and VP2 ( VP2) gene, complete cds. GenBank:AY647977.1 - Human parvovirus 4 isolate VES065CSF NS1, VP1 and VP2 genes , all cds. GenBank:HQ593532.1 - human parvovirus 4 isolate VES085CSF NS1 gene, partial cds; and VP1 gene and VP2 gene, complete cds. GenBank:HQ593531.1 - Parvovirus B19 strain BB-2 NS1, VP1 and VP2 genes, complete cds. G enBank:KF724387.1
[0073] Human norovirus (genogroup I or II) capsid protein, the sequence of which is e.g. For example, it may be shown in or derived from the following sequences: -Norwalk virus: GenBank M87661, NP056821 -Southampton virus: GenBank L07418 -Mexico virus: GenBank U22498 -Setovirus: GenBank AB031013 -Ciba virus: GenBank AB042808 -Rosedale virus: GenBank X86557 -Snow Mountain virus: GenBank U70059 -Hawaii virus: GenBank U07611
[0074] Rabbit hemorrhagic disease virus VP60 protein, the sequence of which is shown, for example, in the following sequence: May be derived from or made up of: -RHDV AST / 89 whole genome: GenBank: Z49271.2 -RHDV N11 complete genome: GenBank: KM878681.1 -RHDV CBVal16 complete genome; GenBank:KM979445.1 SEQ ID NO: 32 SEQ ID NO: 33
[0075] Human papillomavirus L1 protein, the sequence of which is shown, for example, in the following sequence: or may be derived from: -HPV6:GenBank:JN252323.1 -HPV11:GenBank:JQ773411.1 -HPV16:GenBank DQ155283.1 -HPV18:GenBank FJ528600.1
[0076] Hepatitis E virus E2 protein, the sequence of which is shown, for example, in the following sequence: may be derived from: -Hepatitis E virus, whole genome NCBI reference sequence: NC_001434.1 -Porcine hepatitis E virus isolate ITFAE11 capsid protein gene. GenBan k:JN861806.1
[0077] VP1 protein, VP2 protein, and VP3 protein of infectious bursal disease virus Proteins, the sequences of which may be, for example, shown in or derived from the sequences below: stomach: -Infectious bursal disease virus VP1 (VP1) gene, complete cds. GenBan k:AY099457.1 -Infectious bursal disease virus isolate PT VP1 gene, complete cds. GenBa nk:DQ679814.1 -Infectious bursal disease virus isolate OE / G2 VP1 gene, complete cds. Ge nBank:DQ679813.1 -Infectious bursal disease virus isolate OA / G1 VP1 gene, complete cds. Ge nBank:DQ679812.1 -Infectious bursal disease virus isolate HOL VP1 gene, complete cds. GenB ank:DQ679811.1 -Infectious bursal disease virus strain TL2004 VP1 gene, complete cds. Gen Bank:DQ118374.1 -Infectious bursal disease virus isolate CA-K785 VP1 gene, complete cds. GenBank:JF907705.1 -Infectious bursal disease virus isolate D495 VP1 gene, complete cds. Gen Bank:JF907704.1 - Infectious bursal disease virus strain A-BH83 VP1 mRNA, whole cds. G enBank:EU544149.1 -Infectious bursal disease virus strain Cro-Pa / 98 VP1 gene, complete cds. GenBank:EU184690.1 -Infectious bursal disease virus VP2 mRNA, complete cds. GenBank:A Y321509.1 -Infectious bursal disease virus VP2 gene, VP3 gene, VP4 gene, whole c ds. GenBank:M97346.1 -Infectious bursal disease virus VP2 gene, complete cds. GenBank:AF5 08177.1
[0078] Calicivirus capsid protein, the sequence of which is shown, for example, in the following sequence: Or may be derived from: -Feline calicivirus capsid protein gene, complete cds. GenBank: L097 19.1 -Feline calicivirus capsid protein gene, complete cds. GenBank: L097 18.1 -Human calicivirus HU / NLV / Wort against capsid protein (ORF2) ley / 90 / UK RNA, stock HU / NLV / Wortley / 90 / UK. GenB ank:AJ277618.1 -Human calicivirus HU / NLV / This against capsid protein (ORF2) tlehall / 90 / UK RNA, stock HU / NLV / Thistlehall / 90 / UK. GenBank:AJ277621.1 -Human calicivirus HU / NLV / Vale against capsid protein (ORF2) tta / 95 / Malta RNA, strain HU / NLV / Valetta / 95 / Malt a. GenBank: AJ277616.1 -Human calicivirus NLV / Stav / 95 / Nor capsid protein gene, whole c ds. GenBank:AF145709.1 - Bovine enteric calicivirus strain Bo / CV500-OH / 2002 / US capsid protein Gene, all cds. GenBank:AY549155.1 -Human calicivirus NLV / Mora / 97 / SE capsid protein gene, whole cd s. GenBank:AY081134.1 -Human calicivirus NLV / Potsdam 196 / 2000 / DE capsid protein q gene, full cds. GenBank:AF439267.1 - Human calicivirus NLV / 1581-01 / SWE capsid protein gene, whole c ds. GenBank:AY247442.1 -Human calicivirus, Hu / NLV / GII / MD134-10 / 1987 / US Capsule Cid protein gene, complete cds. GenBank:AY030313.1
[0079] Astrovirus ORF2 encoded protein, the sequence of which is shown, for example, in the following sequence: May be derived from or made up of: -Porcine Astrovirus 4 ORF1b gene, partial cds; and ORF2 gene, whole c ds. GenBank:JX684071.1 - Astrovirus MLB1 HK05, complete genome. NCBI reference sequence: NC_0143 20.1 - Astrovirus wild boar / WBAstV-1 / 2011 / HUN, all genotypes Mu. NCBI reference sequence: NC_016896.1 -Human astrovirus BF34, complete genome. NCBI reference sequence: NC_024472. 1 - Astrovirus MLB1 strain Hu / ITA / 2007 / PR326 / MLB1 RNA dependent RNA polymerase (ORF1b) gene, partial cds; and capsid protein (ORF2) gene, complete cds. GenBank:KF417713.1 - Human astrovirus 5 strain Hu / Budapest / HUN5186 / 2012 / HU N nonstructural protein (ORF1a) gene and nonstructural protein (ORF1b) gene , partial cds; as well as the capsid protein (ORF2) gene, full cds. GenBan k:KF157967.1. -Human Astrovirus 1 isolate Shanghai capsid protein (ORF2) gene child, all cds. GenBank:FJ792842.1 - Human astrovirus type 8 orf2 gene for the capsid protein. GenBan k:Z66541.1
[0080] Influenza virus HA protein, NA protein and M1 protein, and their sequences The sequence may, for example, be as shown in or derived from the following sequences: -SEQ ID NO: 30 - Influenza A virus (A / duck / Chiba / 25) against hemagglutinin -51-14 / 2013(H7N1)) HA gene, complete cds. GenBank:AB8 13060.1 - Synthetic construct hemagglutinin (HA) mRNA, full cds. GenBank: DQ868 374.1 - Influenza virus A (A / swine / Shandong / 2 / 03(H5N1 ))Hemagglutinin (HA) gene, complete cds. GenBank:AY646424.1 -cDNA encoding influenza A HA. GenBank: E01133.1 - Influenza A virus (A / swine / Korea / S452 / 2004(H9 N2)NA gene, complete cds. GenBank:AY790307.1 -Influenza A virus (A / Thailand / 2(SP-33) / 2004(H 5N1)Neuraminidase (NA) gene, complete cds. GenBank:AY5551 52.3 - Influenza A virus (A / swine / Binh D) neuraminidase oung / 02_16 / 2010(H1N2))NA gene, all cds. GenBank :AB628082.1 -Influenza A virus (A / chicken / Jalgaon / 8824 / 200 6(H5N1))Neuraminidase (NA) gene, complete cds. GenBank:DQ8 87063.1 -Influenza A virus SC35M M2 and M1 genes, complete cds. Bank:DQ266100.1 -Influenza virus type: Leningrad / 134 / 47 / 57(H2N2)M 1 and M2 RNA, all cds. GenBank: M81582.1 -Influenza A virus SC35M M2 and M1 genes, complete cds. Bank:DQ266100.1 -Influenza A virus against matrix protein 2 and matrix protein 1 (A / Tochigi / 2 / 2010(H1N1)) M2 gene, M1 gene, all cds GenBank:AB704481.1
[0081] The hepatitis B core and surface antigens, the sequences of which are shown, for example, in the following sequences: may be derived from: -Hepatitis B virus strain HBV248 pre-core protein gene and core protein gene , all cds. GenBank:KP857118.1 -Hepatitis B virus strain HBV401 precore protein gene and core protein gene , all cds. GenBank:KP857113.1 -Hepatitis B virus strain HBV403 precore protein gene and core protein gene , all cds. GenBank:KP857068.1 -Hepatitis B virus S gene, partial cds, isolate for hepatitis B surface antigen: B050 3327(PTK). GenBank:AB466596.1
[0082] The recombinant proteins mentioned above are not proteins endogenously produced by the pupae. For example, the recombinant protein may be expressed by pupae, such as pupae of Hyalophora cecropia species. For example, the recombinant protein is a cecropin. Not A or attacin.
[0083] The pupae of the present invention may be silk-free pupae or may be inside a silk cocoon. If the pupa does not contain silk, those skilled in the art know how to remove the cocoon silk. For example, the silk filaments are preferably treated with a salt, preferably a salt of hypochlorous acid (HClO), preferably A solution of sodium chlorite (NaClO) (referred to herein as a dissolving solution) As shown in Figure 3, this procedure can be carried out using a specially designed The method may be automated by a device that is
[0084] Use of the pupae of the present invention for the expression of recombinant proteins The pupae of the present invention, in any of its variants, can be used for the expression of recombinant proteins. Thus, the present invention relates to recombinant proteins, preferably those as detailed herein above. There is provided the use of the pupa of the invention for the expression of a recombinant protein.
[0085] Methods for Producing Recombinant Proteins of the Invention The present invention also relates to recombinant proteins (as already described above, endogenously expressed by the pupae) The present invention provides a method for producing a protein (preferably not a protein produced by a gene encoding a gene encoding a nucleotide sequence) by, for example, The method for obtaining at least one recombinant protein according to the invention comprises the steps of: (a) preparing pupae; (b) Autographa californica multicapsid nuclear polyhedrosis virus (AcMN PV) into the pupae of step (a); (c) carrying out the steps (a) and (b) for a period of time sufficient to express at least one recombinant protein. b) incubating the inoculated pupae; (d) obtaining pupae containing at least one recombinant protein; (e) optionally harvesting the at least one recombinant protein; (f) optionally purifying at least one recombinant protein; It comprises or consists of:
[0086] The pupae of step (a) of the above method are preferably cultured according to the present invention as described in detail above. The pupae of step (a) may be pupae of the order Lepidoptera. Preferably, the genus Trichoplusia, the genus Lachyplusia, the genus Spodoptera, the genus Heliothis, the genus Manzu Mosquitoes, Helicoverpa, Ascarafa or Samia, preferably Trichoplusia; Lachypursia, Spodoptera, Heliothis or Helicoverpa, more preferably Trichoplusia ni spp., Lachypurus nu spp., Spodoptera frugiperda spp., Heliotropia Helicoverpa virescens species, Helicoverpa armigera species, Helicoverpa zee species, Manzuca sexta species, Ascalapha odorata species or Samia cynthia species, more preferably Preferably, the pupae belong to the species Trichoplusia ni. As already mentioned above, the pupae It may contain a nucleic acid sequence that allows the expression of a recombinant protein. Thus, these pupae express transcriptional regulators at levels above the endogenous levels obtained during baculovirus infection. Protein IE-1, protein IE-0 and / or their fragments functioning as a promoter The vector may include a nucleic acid sequence that allows for expression of the compound at greater than endogenous levels (see "The Invention" above). (See “Pupa”)
[0087] The pupae of step (a) above may be developed from eggs. For example, the pupae of step (a) above may be For example, in specially designed disposable or reusable incubation chambers, for 15 to 18 days. Alternatively, the pupae of step a) may be provided already in pupal form. good.
[0088] When the pupae of step (a) above are inside the cocoon, they produce the recombinant protein of the present invention. The method may further comprise the step of removing the cocoon filaments from the pupae. For example, 0.1% to 5% weight / volume, for example, 0.1%, 0.2%, 0.5%, 1%, 3% or A salt containing hypochlorous acid (HClO) at a concentration of 5% weight / volume, preferably sodium hypochlorite It is preferable that the pupae be dissolved in a solution of sodium chloride (NaClO). The pupae may be immersed in a solution of sodium hypochlorite at a concentration of 1000 mg / kg / day or sprayed with the solution. The dissolution of the cocoon filaments may take several seconds to several minutes. The selection of the cocoon threads can be carried out in a semi-automated or automated form (robotized) when the pupae are inside the cocoon. In this regard, it is preferable to carry out the selection of silkworms (selection of silkworms with high silk solubility) using the method described above. The fact that the cocoons of some species, such as Bombyx mori, are thick is indicative of the fact that they are different from other genera or species. (Trichoplusia genus, especially Trichoplusia ni species, etc.) The pupae of Trichoplusia genus, especially Trichoplusia ni species, have a less dense silk cocoon and dissolve easily. This allows the entire process to be carried out in an automated or semi-automated form, thus improving efficiency. This means benefits that can increase the cost and lower the overall cost
[0089] The cocoons are preferably heated in a compressed air turbulence to reduce the time required for the silk cocoons to dissolve. a recipient containing a dissolution solution which is applied to the cocoons by air turbulence; The silk-free pupae can then be removed using a semi-automatic machine to remove traces of the lysing solution. After washing in the washing container, it may be air dried.
[0090] Therefore, silk-free pupae are preferred since it is easier to carry out step (b) later. Therefore, pupae with very dense cocoons are less preferred. The pupae of the A. mori have a very dense, thick, compact cocoon and, as described above, for a few minutes, It cannot be easily removed by dissolving in salt solutions. The same is true for the pupae of Bombyx mori and / or Hyalophora sexta. The Lopia pupal cocoons must be removed by hand.
[0091] In contrast, the pupae of other species, such as T. ni, contain less dense silk cocoons and are more dense than those described above. Therefore, it can be easily dissolved so that it can be easily processed by automated or semi-automated procedures. These cocoons can be removed, indicating that these pupae express the recombinant protein of the present invention. For the method of producing the recombinant baculovirus (step (b)), This facilitates scale-up for obtaining pupae that have already been cultured.
[0092] After removing the cocoon threads, the pupae are soaked in water to remove traces of salt solution (e.g., sodium hypochlorite). Preferably, the silk-free pupae are then dried and washed with water before carrying out step (b). For example, the silk-free pupae may be stored at low temperatures (e.g., 4°C) before carrying out step (b). Alternatively, it may be stored at low temperature (e.g., 4°C) for up to one month.
[0093] Therefore, the present invention also provides (a) providing a pupa contained in a cocoon (preferably a pupa of the invention as described above); (b) a solution of a salt, preferably a salt of hypochlorous acid, as described in detail above, treating said pupae contained in the cocoons with a solution of sodium hypochlorite; (c) obtaining silk-free (preferably essentially sterile) pupae; A silk-free pupa (preferably a silk-free pupa belonging to Lepidoptera, preferably the present invention) comprising The present invention provides a method for producing a pupa of a fungus, which is a fungus.
[0094] Thus, the present invention also provides an essentially silk-free (i.e., cocoon-free) silkworm of the present invention. In a preferred embodiment, the essentially silk-free pupa of the present invention is Bombyx mori. In a preferred embodiment, the essentially silk-free pupa of the present invention does not belong to the Hyaluronan species. In a preferred embodiment, the essentially silk-free silk of the present invention does not belong to the species Fora cecropia. The pupae are Trichoplusia, Lachyplusia, Spodoptera, Heliothis, and Manzuca. Genus Helicoverpa, Ascarafa, or Samia, preferably Trichoplusia, La It belongs to the genus Cyprusia, Spodoptera, Heliothis, or Helicoverpa. In an embodiment, the essentially silk-free pupae of the present invention are A. nus species, Spodoptera frugiperda species, Heliothis virescens species, Helicobacter Pa. armigera species, Helicobacter pa gyi species, Manduca sexta species, Ascara odo lata species, or Samia cynthia species, and more preferably Trichoplusia ni species.
[0095] Step (b) of the method of the present invention comprises the step of: Step (a) by recombinant baculovirus derived from AcMNPV The recombinant baculovirus that may be contained in the pupae of the present invention is described in detail above. An exemplary schematic diagram is shown in FIG. 4B. Thus, in step (b), In order to provide a pupa according to the present invention containing a recombinant baculovirus, It is preferable to inoculate the recombinant baculovirus. In step (b) of the method for producing a recombinant protein of the present invention, the pupae of the present invention are The present invention discloses a recombinant baculovirus that can be inoculated into the , a recombinant protein, preferably a combination selected from the group defined herein above. It contains a nucleic acid sequence (expression cassette) that encodes the recombinant protein.
[0096] Subsequent inoculation with recombinant baculovirus is easier and can be performed automatically or semi-automatically. Silk-free pupae are preferred because they are possible and facilitate scale-up and reproducibility of the method. I wish.
[0097] The inoculation of the recombinant baculovirus according to step (b) is well known to those skilled in the art. This can be done by known techniques. "Inoculation" as defined herein refers to the introduction of a substance into the body. In this case, it refers to the introduction of a recombinant baculovirus into the pupa. This is sometimes called "injection." The larvae are inoculated with the baculovirus, The process may also be referred to herein as "infection of larvae with baculovirus."
[0098] The inoculation is carried out by injecting a predetermined amount of a solution containing at least one baculovirus into the pupae. The injection is preferably carried out by drilling a pupa and injecting the baculovirus into the pupa. This is preferably done using a needle that dispenses a predetermined amount of a solution containing the The pupae may be placed, for example, in a matrix or array of small holes, and the inoculation device Alternatively, a robot (described below) may automatically administer baculovirus into the pupae. For example, pupae may be placed in a matrix (or array) of small holes and then incubated with an inoculation device or robot. A robot (e.g., equipped with a needle on a robotic arm) automatically places the needle in the small hole, and the needle penetrates the hole in the lid. The matrix is provided with a lid having a central hole through which the needle can access the pupa. The body of the pupa is penetrated, for example, by about 1 to 5 mm, preferably about 3 mm (this The baculovirus solution is then injected into the pupa. The robot delivers a precise amount of baculovirus (e.g., approximately 0.5 μg / ml containing baculovirus) to the pupae. Administer a volume of solution between microliters and 10 microliters, preferably about 5 μl The robot may be equipped with a precision pump that can deliver baculovirus to pupae at a precise location. The device may also include an arm with one or more needles through which the drug can be injected. Once the robot is removed from the hole, the pupa can be easily removed thanks to the matrix lid on which it is placed. The pupa is left in the matrix hole, and the matrix is inserted so that only the needle can pass through the hole. The hole in the lid of the needle is smaller than the pupa, so when the robot arm removes the needle from the pupa, the pupa escapes through the small hole. The needle is not removed, and thus the needle is removed from the pupa and the pore matrix, leaving the pupa in the pore. This preferred arrangement makes the inoculation process automatic, rapid, efficient and highly reproducible. This is possible (all pupae receive the same amount of solution containing baculovirus in the same procedure). The robot may be mobile and can incubate about 3,000 to about 10,000 pupae per hour. Some inoculation needles can inoculate baculovirus into pupae at high speed (i.e., inject baculovirus into pupae at a precise position). The catheter may have a needle through which the vein virus can be inoculated or injected.
[0099] For example, each pupa is inoculated with a quantity of baculovirus of approximately 50 or more plaque forming units (PFU). For example, about 50, about 100, about 500, about 1000, about 5000, about 10000, Approx. 15,000, Approx. 20,000, Approx. 25,000, Approx. 30,000, Approx. 40,000, Approx. 5,000 Inoculation of 0, about 60,000, about 75,000 or more PFU (even about 1,000,000) into each pupa For example, as already mentioned above, the baculovirus is in solution and therefore A specific amount of a solution containing a baculovirus is injected into the pupa. For example, the solution may contain a baculovirus. For example, the solution may be a cell culture medium containing 1×PB containing baculovirus. S Solution of pH 7.4, 1 mM PMSF (protease inhibitor), and 5 mM DTT For example, the pupae may be in a buffer solution containing baculovirus such as 0.5 μl of baculovirus. 1 to 10 μl, for example about 0.5 μl, for example 1 μl to 10 μl, for example about 1 μl, about 2 μl A solution containing baculovirus in an amount of about 1 μl, about 3 μl, about 5 μl, about 7 μl, or about 10 μl is For example, each pupa can be inoculated with 0.5 μl to 1000000 PFU. Receive 10 μl of solution.
[0100] Thanks to the automation of the inoculation, the robot can inoculate more than 3,000 vaccines per hour, for example, about 300 per hour. The robot can inoculate from about 10,000 to about 10,000 pupae. Suitable for delivering fluid to the pupae provided in
[0101] Step (c) of the method of the present invention comprises generating a vector sufficient for expression of at least one recombinant protein. and incubating the inoculated pupae of step (b) for a period of time sufficient to inoculate the pupae. The incubation step may be for at least about 72 hours, e.g., for about 72 hours (post-inoculation), about 96 hours, or 100 hours, 125 hours, 150 hours, or 168 hours or more The incubation period is preferably about 96 to 168 hours after inoculation. The inoculation step is preferably performed within about 72 to 168 hours after inoculation. The experiment was carried out in an incubator with no light or humidity control at a temperature of approximately 22°C to 28°C. The inoculated pupae (preferably placed in the holes of the matrix) are then cultured in the above-mentioned manner. The matrix may be left in the pores for a period of time (incubation). In this state, the pupae are removed from the matrix and placed in a pouch or container for the incubation period. (Incubation is completely (Preferably in a container with gas exchange rather than in a closed container) .
[0102] Those skilled in the art can determine the optimum conditions for each pupa and each recombinant protein based on previous experiments, depending on the protein to be expressed. Calculate the incubation time and conditions required for the protein.
[0103] Step (d) of the method of the present invention comprises incubating at least The method further comprises obtaining pupae containing at least one recombinant protein. Pupae containing proteins can be collected from the matrix / array (or incubation site) These pupae, which contain at least one recombinant protein, can be used for further processing (frozen or frozen). For example, pupae containing at least one recombinant protein may be stored in a lyophilized state. The pupae may be packed in a package (preferably under vacuum). The package containing the pupae may then be stored. , transported, and / or further processed.
[0104] The present invention also includes a pupa of the present invention, preferably comprising at least one recombinant protein. Preferably, the pupae are packaged under vacuum, and the package contains the protein of the present invention. The packaging may therefore be, for example, vacuum frozen or freeze-dried to avoid oxidation. This allows for easier handling and longer storage period.
[0105] Alternatively, the pupae obtained according to step (d) of the above method may be frozen and stored for further processing. For example, the pupae may be stored at about -20°C immediately after collection or at about For example, pupae containing at least one recombinant protein may be frozen at -80°C. The recombinant protein may be frozen, for example at a temperature of about -20°C to -70°C, until extraction. Pupae containing the recombinant protein may be cryopreserved for long periods of time, e.g., for more than a year. .
[0106] The (optional) step (e) of the method of the invention optionally comprises the step of: The method includes collecting at least one of the pupae obtained in step (d). We know the methods and protocols for harvesting recombinant proteins. The methods and / or protocols may depend on the nature of the expressed recombinant protein.
[0107] For example, the protein can be prepared by homogenizing pupae in the presence of a buffer, preferably at a neutral pH. By adjusting the size (e.g., blender homogenizer or rotor-stator homogenizer), for at least a few seconds / minutes in a homogenizer machine such as a homogenizer mixer The extraction may be performed for 10 minutes (minutes), and the buffer may contain antioxidants (reducing agents), protease inhibitors, and It is preferable to include a suitable detergent. For example, the above buffer contains about 1 mM to 25 mM A reducing agent and about 0.01% to 2% (volume / volume) of a cleaning product. It is preferred to further comprise a mixture of protease inhibitors.
[0108] After homogenization, the extract is sonicated and / or centrifuged (e.g., at 15,000 G to 2,000 G). 0G) to eliminate insect remains and filter them out.
[0109] For example, an extraction method (a method for collecting at least one recombinant protein contained in the pupae) The protocol includes physical disruption of pupae, centrifugation, tangential flow filtration steps, ultrasonic treatment, and These techniques include purification, chromatography, and / or sterile filtration.
[0110] In a preferred embodiment, the viscosity of the homogenate is improved using diatomaceous earth (e.g., Celite). This can be reduced by incubation with ethanol (filtration) or by including a protein precipitation step. can.
[0111] The extract may be prepared by any of a number of filters available to the skilled artisan for selection depending on the nature of the recombinant protein. The diafiltration process can be carried out by tangential flow filtration using a filter. Thus, the buffer may be changed (eg, in the same tangential flow filtration device).
[0112] The (optional) step (f) of the method of the invention optionally comprises the step of: Those skilled in the art are familiar with protein purification techniques. For example, purification This can be achieved by chromatographic purification, filtration or ultracentrifugation.
[0113] A purified recombinant protein can thus be obtained. A schematic diagram is shown in Figure 17.
[0114] The recombinant proteins obtainable by the method of the present invention have a high purity and can be used in vaccines, diagnostics, It may be used in diagnostics, cosmetics, or therapy.
[0115] Methods for Producing Recombinant Baculoviruses of the Invention The present invention further comprises: (a) preparing pupae; (b) Autographa californica multicapsid nuclear polyhedrosis virus (AcMN PV) (step (a) transfecting pupae of (c) inoculating the culture medium of step (b) for a period of time sufficient to produce a recombinant baculovirus. Incubating the exposed pupae; (d) obtaining pupae containing the recombinant baculovirus; (e) optionally harvesting the recombinant baculovirus; (f) optionally purifying the recombinant baculovirus; The present invention provides a method for producing a recombinant baculovirus, comprising:
[0116] The pupae provided in step (a) are preferably silk-free pupae as defined above. The genera are Trichoplusia, Lachyplusia, Spodoptera, Heliothis, and Manduca. Helicoverpa, Ascarafa, or Samia, preferably Trichoplusia, Lachypodium Lucia, Spodoptera, Heliothis, or Helicoverpa, more preferably Trichophyton Prussia ni spp., Lachypurusia nu spp., Spodoptera frugiperda spp., Heliotis vulgare Helicoverpa armigera species, Helicoverpa zee species, Manzuca sec Ascala species, Ascala odorata species, or Samia cynthia species, more preferably Trichoderma species. It is preferable that it belongs to the species Coplusia ni.
[0117] In step (b), the pupae of step (a) are cultured to produce multicapsid nuclei of Autographa californica. To produce recombinant baculovirus derived from AcMNPV Transfect with the appropriate bacmid vector.
[0118] This step (b) also corresponds to step (b) of the method for producing a recombinant protein described above. ) but instead of inoculating with baculovirus, inoculate with a bacmid vector. seeding), i.e. automatically or semi-automatically (also described below) using the device of the invention The apparatus may be referred to as an "inoculation process" since it can be used to carry out the above-described Transfer vectors and / or vectors are inoculated into pupae by injection with a needle. A predetermined amount of solution containing cumid is placed on the pupae (preferably in a small-hole matrimonial tube with a tap having a hole). The vaccine may also be administered to a patient in a vaccinated animal (placed in a box).
[0119] Bacmid vectors can be used, for example, as cloning vectors, donor vectors, transfer vectors, The sequential generation of a vector, a bacmid vector, and finally a bacmid vector, is known to those skilled in the art. For example, the production of bacmid vectors can be carried out by the procedures described in International Publication No. WO 2005 / 023363. This is described in published patent application no. 014 / 086981.
[0120] In a preferred embodiment, the transfer vector and / or bacmid is Proteins that function as transcriptional regulators above endogenous levels obtained during viral infection The protein IE-1, the protein IE-0 and / or their fragments are expressed at levels exceeding the endogenous levels. and any suitable nucleic acid sequence for driving the expression of a recombinant protein. and a recombinant homology region (hr) operably linked to a promoter, or These nucleic acid sequences have already been described above. For example, the protein IE-1, The nucleic acid sequences allowing the expression of the protein IE-0 and / or fragments thereof are (a) a nucleic acid comprising a nucleotide sequence shown in any one of SEQ ID NOs: 1 to 5; (b) a nucleotide sequence having at least 7 parts by weight, 0%, preferably at least 75%, more preferably at least 80%, more preferably At least 85%, more preferably at least 90%, and most preferably at least 9 It has 5% sequence identity with baculovirus and functions as a transcriptional regulator in recombinant baculovirus. a nucleic acid sequence encoding a protein to be obtained; (c) a coding sequence including an amino acid sequence shown in any one of SEQ ID NO:6 to SEQ ID NO:9; A nucleic acid sequence for coding the nucleic acid sequence, (d) a sequence that is at least 70% identical to any one of the amino acid sequences shown in SEQ ID NO:6 to SEQ ID NO:9; , preferably at least 75%, more preferably at least 80%, more preferably at least at least 85%, more preferably at least 90%, and most preferably at least 95% and can function as a transcriptional regulator in recombinant baculoviruses. A nucleic acid sequence encoding an amino acid sequence, It is preferably selected from the group consisting of:
[0121] Furthermore, the promoter driving the expression of the recombinant protein is (a) a compound represented by any one of SEQ ID NOs: 10 to 14, preferably SEQ ID NOs: 11 to 14 A nucleic acid comprising a nucleotide sequence as set forth in any of SEQ ID NOs: 13, and (b) a sequence capable of functioning as a promoter in a recombinant baculovirus; The sequence shown in any one of SEQ ID NO: 10 to SEQ ID NO: 14, preferably SEQ ID NO: 11 to SEQ ID NO: 1 3, which has at least 70%, preferably at least 7 5%, more preferably at least 80%, more preferably at least 85%, more preferably or at least 90%, and most preferably at least 95% sequence identity to array, It is preferred that the nucleic acid is selected from the group of nucleic acids comprising:
[0122] The recombinant homologous region (hr) is the sequence (hr1) shown in SEQ ID NO:21. A recombinant promoter, a sequence encoding a transcriptional regulator, and an enhancer region are preferably used. The nucleic acid sequence comprising the combination of the region is selected from the group consisting of SEQ ID NO: 15 to SEQ ID NO: 20. It is preferable that
[0123] The vector with which the pupae are inoculated is preferably a bacmid.
[0124] Step (c) comprises the step (b) of: ) pupae inoculated with T. ni during this period. The incubation time may range from about 72 hours to about 7 days, depending on the viral dose and temperature. A period of time sufficient for baculovirus to be produced can be calculated.
[0125] Thereafter, pupae containing the recombinant baculovirus are obtained (step (d)). The pupae containing the urovirus may be stored for further processing, e.g., by suppressing the oxidation process. To facilitate their manipulation and to extend their safe storage time, the pupae may be vacuum packed. For example, the pupae containing the recombinant baculovirus may be frozen prior to further processing. (e.g., at -20°C to -80°C). For example, recombinant baculovirus may be The pupae containing the spores may be freeze-dried.
[0126] Optionally, the recombinant baculovirus may be harvested and purified (step (e) and step (f)). f).
[0127] Apparatus of the invention The present invention also relates to a precision pump, a mobile mechanical arm, and a pupa (preferably the pupa of the present invention). Preferably, the pupae are silk-free and are of the order Lepidoptera, preferably Trichoplusia. , Lachypurusia, Spodoptera, Heliothis, Manduca, Helicoverpa, Aspergillus, Carafa or Samia, preferably Trichoplusia, Lachyplusia, Spodoptera Heliothis, Heliothis or Helicoverpa, more preferably Trichoplusia ni, Rachis Prussia nu species, Spodoptera frugiperda species, Heliothis virescens species, Heli Koberupa armigera species, Helicoverpa gii species, Manduca sexta species, Ascarafa A fluid (preferably belonging to the species Bacillus odorata or Samia synthia) A (removable) needle suitable for injecting the solution containing the viral vector or the bacmid vector The present invention provides an apparatus (also referred to as a robot in the present invention), comprising:
[0128] As described in detail above, the device can easily position the pupae automatically. Thus, the pupae may be provided in a matrix (or array), i.e., the pupae are inserted into the holes of the matrix. The matrix is preferably provided with taps having holes smaller than the pupae. It is preferable that the hole be closed (i.e. the pupa cannot pass through it).
[0129] The device defines the position of the needle (and / or the position of the mechanical arm) and / or the tip of the needle. Distance from the end to the pupa and / or the needle penetration distance to the pupa and / or the liquid ( A computer program is used to calculate the volume of the solution (preferably containing a baculovirus or bacmid vector). Furthermore, the device of the present invention may further include a computer program. Alternatively, the device may further comprise a computer program for calculating the time between the various inoculations. The device may further comprise a camera to determine the position of the needle.
[0130] In a preferred embodiment, the fluid injected by the device of the present invention is a recombinant baculovirus. In another embodiment, the fluid injected by the device of the present invention comprises Suitable for producing recombinant baculoviruses derived from AcMNPV, as described above in The bacmid vector includes
[0131] The device of the present invention comprises step (b) of the method for producing a recombinant protein of the present invention, and It is suitable for carrying out step (b) of the method for obtaining a recombinant baculovirus of the invention.
[0132] For example, the device of the present invention may have a volume in the range of about 0.5 μL to about 10.0 μL, for example about 0.5 μL , for example, about 1 μL to about 10 μL, for example, about 1 μL, about 2 μL, about 3 μL, about 5 μL, about 7 μL 1 μL, or approximately 10 μL of fluid volume is suitable for injecting (inoculating) pupae.
[0133] For example, the needle provided in the device of the present invention is inserted into the pupa by about 1 mm to about 4.5 mm, preferably about It can be penetrated at a distance of 3 mm.
[0134] For example, the device of the present invention is equipped with several movable inoculation needles and can produce approximately 300 pupae per hour. Fluid (preferably baculovirus or bacmid vector) at a rate of 0 to 10,000 cells / ml. A solution containing the same can be inoculated.
[0135] For example, the fluid injected by the device of the present invention is preferably about the dose injected into each pupa. 50PFU~10 6 The device of the present invention contains baculovirus in an amount of PFU. , greater than about 50, greater than about 100, or greater than about 500 plaque forming units (PFU) of baculovirus. Inject (inoculate) each pupa with a dose of virus, e.g., about 50, about 100, about 300, about 50 0, approx. 1000, approx. 5000, approx. 10000, approx. 15000, approx. 20000, approx. 2500 0, approx. 30,000, approx. 40,000, approx. 50,000, approx. 100,000, approx. 500,000 or more Inoculate each pupa with approximately 1 million PFU of virions, for example approximately 1 million PFU.
[0136] The device of the present invention is capable of injecting a desired volume of fluid (preferably baculoyl) into the pupa with high precision. The system is equipped with a highly precise pump that allows the inoculation of a solution containing a vaccinia virus or a bacmid vector. It is preferred.
[0137] The device of the present invention is suitable for delivering fluids to pupae provided in a matrix or array. do.
[0138] The apparatus of the present invention is designed to administer the baculovirus-containing liquid to each pupa for a period of time sufficient to achieve this. The method further comprises a computer program for calculating the inoculation time and / or the time between inoculations of the pupae. It is preferable to do so.
[0139] Preferably, the device of the present invention further comprises a camera for determining the position of the needle.
[0140] The present invention further provides an apparatus for selecting silk (silk selection apparatus). Examples of the silk selection apparatus of the present invention are A schematic diagram of the system is shown in Figure 3 (semi-automatic device for silk selection from T. ni cocoons).
[0141] As described above, the silk selection device of the present invention (also called "silk selection machine") is a silk dissolving At least one container containing a liquid is provided, for example, the container contains hypochlorous acid. The first container also includes a system for releasing liquid through the rearing module containing the cocoons (such as a The system preferably comprises a pupa-sequestering device that is adapted to dissolve the silk surrounding the pupa more efficiently. The dissolving solution was applied to the cocoons by compressed air perturbation, and the time it took to dissolve the silk cocoons was measured. It is preferable to decrease it.
[0142] The silk selection device of the present invention preferably further comprises a second container, which is adapted for washing. A cleaning container containing a solution such as water suitable for removing traces of silk and silk dissolving solution from the pupae. Spraying the solution (preferably water) onto the pupa. It is preferable that the lid of this container has a system for providing air to dry the pupae. Therefore, after washing the pupae, it is preferable to air-dry the pupae. Instead, the pupae contain no silk and are not prepared for infection or for storage (refrigeration) until use. is.
[0143] [Table 1] EXAMPLES
[0144] Example 1. Production of T. ni pupae Contains hundreds of larvae that have developed from egg to pupa over 15-18 days and can be reused Insect larvae were raised in standard or disposable rearing vessels (Figure 1). Afterwards, the entire rearing vessel or the collected pupae were The specimen is immersed in a solution of sodium hypochlorite with a concentration of 0.1% weight / volume to 5% weight / volume. The silk fibers of the cocoons were dissolved by either soaking in water or spraying the pupae with the solution. After the silk was dissolved for a few minutes, the pupae were placed in water. The pupae were then washed with 50 mL of 100 mL of 100% sodium hypochlorite to remove traces of hypochlorite. The pupae were then dried and inoculated with baculovirus. As can be seen in Figure 2, this process resulted in the formation of T. diplocarpon silk tree. The silk treats are low density, so they can be grown in the same manner as Bombyx mori cocoons. Bombyx mori cocoons require no manual intervention to release the pupa. whereas T. nigricans silk is easily dissolved and can be prepared by automated or semi-automated procedures. and are ready to be injected with recombinant baculovirus for recombinant protein production. This makes it easy to scale up the production of ready-made pupae.
[0145] Example 2. Enhancers operably linked to chimeric promoters (p6.9 and p10) Dual recombinant baculoviruses containing the ser sequence (hr1) and overexpressing IE IE-1 and IE-0 transactivators mediate recombinant protein production in insect pupae It is very efficient Enhanced by the baculovirus homologous repeat sequence hr1, overexpressed IE-1 factors and and IE-0 factors transactivate the chimeric promoter. Recombinant protein expression was compared between that obtained using conventional baculovirus and that obtained using insect pupae ( The gene encoding the recombinant green fluorescent protein (GFP) was compared in T. niger. , by conventional means, under the control of the polyhedrin promoter, The cassette containing the regulatory elements mentioned above was cloned into the virus (Figure 4A). Another AcMNPV baculovirus modified with a TB expression cassette also expresses GFP. The virus was generated containing the gene encoding the virion (Figure 4B). and a robotic arm capable of injecting the virus at a precise location. Pupae were infected with 50,000 PFU of each baculovirus by an inoculation robot (Figure 5A). ) Pupae were placed into the matrix of pores with a lid containing a hole in the center of each pore (Figure 5B). The inoculation needle (which is movable) accesses the pupa through a hole and penetrates a few millimeters into the pupa to inject the baculovirus. The virus was injected (Figure 5C). The recombinant virus contained in the pupa is injected into the pupa, and the pupa is held in place by the lid while the needle is removed. The inoculation robot is at least six times faster than manual inoculation by a skilled practitioner. , demonstrating an inoculation rate of at least 3000 pupae per hour.
[0146] After an incubation period of 96 to 168 h after inoculation, pupae were collected and incubated with antioxidants. , a neutral pH buffer containing a protease inhibitor, and a non-ionic detergent (e.g., 1x PBS pH 7.4 + 5mM dithiothreitol (DTT) + 1mM phenyl fluoride Presence of PMSF + 0.1% Brij35 + 0.5% Sarkosyl The protein was extracted using a homogenizer. The extract was analyzed by SDS-PAGE electrophoresis and the gel was The results were stained with sea blue (Figure 6A). The estimated GFP protein production yield (expressed as milligrams per unit of biomass) ) was calculated by densitometry using a bovine serum albumin (BSA) curve. This analysis was performed using conventional baculovirus (i.e., without any other A baculovirus containing a polyhedrin promoter without any regulatory elements was used. The results were compared with those obtained by baculovirus genetically modified with the TB cassette. The GFP production in the pupae was increased by approximately 5.6-fold (Figure 6B).
[0147] Example 3. Expression of various proteins by TB modified baculovirus in T. niger pupae The TB (TopBac) expression cassette (SEQ ID NO: 17) was used for further protein expression. To analyze the benefits of using TB, two genes were cloned into the TB cassette and Similar to conventional baculoviruses that express genes under the control of the polh promoter, The corresponding recombinant baculovirus was obtained (Figure 7). The two genes used for this study were porcine circovirus 2 (PCV2a) GER3 strain-derived Protein Cap (SEQ ID NO: 25 and SEQ ID NO: 27) according to type, and virus strain A / PR Hemagglutinin (SEQ ID NO: 1) from influenza virus (H1) derived from 30 and SEQ ID NO: 31). The cassette contains a polyhedrin promoter for expressing proteins, but TopB ac (conventional baculovirus unmodified with the TB expression cassette) and TB The (+) baculoviruses were used in Example 2 for their production ability in T. ni pupae. The same infection and protein extraction protocols were used and compared as described previously.
[0148] Conventional (TB(-)) baculovirus or TB modified (TB(+)) baculovirus Production yield in infected pupae (expressed in milligrams per unit of biomass) mediated by Comparison of the expression cassettes (Table 1) showed that for both proteins, the expression cassette TB increased the production yield. In the case of the porcine circovirus Cap protein, Protein production when pupae were infected with TB modified baculovirus compared to pupae infected with The HA protein of influenza virus increased by 2.79 times (Fig. 8). This increase was 2.04-fold (Figure 9). These results indicate that the TB cassette is It was confirmed that the expression of the recombinant protein significantly increased the production of the recombinant protein in Escherichia coli.
[0149] Example 4. Recombinant protein production in baculovirus-infected T. ni pupae is higher than in larvae. is also efficient Five recombinant proteins in TB(+) baculovirus in pupae and larvae of T. ni A relative expression of the quality was performed. The expressed proteins were as follows: GFP (SEQ ID NO: 23), Cap (SEQ ID NO: 25), HA (SEQ ID NO: 30), and two rabbit hemorrhagic calcitonin antibodies. Viral strains (RHDV genogroup 1 and RHDVb; SEQ ID NO: 32 and SEQ ID NO: 33 VP60 (capsid protein) derived from the larvae of P. cerevisiae (Figure 10). The infected insects (larvae and pupae) were then infected with the corresponding TB(+) baculovirus of U. Soluble protein extracts were stained with Coomassie blue. The results were analyzed by S-PAGE electrophoresis (Figures 11A, 12A, 13A, and 14A). The recombinant protein was quantified by densitometry using a BSA curve to determine the production yield. was expressed as milligrams per unit of biomass (Figures 11B, 12B, 13B and In both cases, pupae outnumbered larvae by an increase ratio of 1.06 to 3.64. The recombinant protein was expressed.
[0150] Example 5. Production of recombinant virus-like particles (VLPs) in T. niger pupae To demonstrate the production of VLPs in infected pupae, the two rabbit mosquito species analyzed in Example 4 were TB(+) baculovirus expressing VP60 protein derived from Lys virus strain Protein extracts from infected pupae were processed for VLP purification. 2% Sarkosyl (Sigma) in 2 M sodium phosphate, 0.1 M NaCl, pH 6.0 ) and 5 mM EDTA (Sigma), and protease inhibitors (Complet VLPs were isolated from infected pupae 96 hours after infection by centrifugation in the presence of 100 mM NaCl. The DNA was extracted and incubated overnight at 4°C. They were then incubated at 37°C for 1 hour with DNAse. After additional centrifugation (2000 × g, 5 min), the cells were treated with PBS. The supernatant was subjected to ultracentrifugation (131,453 × g; 2.5 hours). The samples were extracted twice with 100 μl (Sigma) and subjected to a second ultracentrifugation (131,453 × g; 2.5 h). Finally, the pellet was resuspended in 1x PBS and stored at 4°C until analysis.
[0151] The precipitate was analyzed by transmission electron microscopy performed by conventional means. Purified VLPs (approximately 5 μl) were applied to glow-discharged carbon-coated grids for 2 min. The specimens were negatively stained with 2% (wt / vol) aqueous uranyl acetate. The images were recorded using an Ex microscope (JEOL, Japan). As shown in Figure 14, VLPs of the expected size and shape were observed in the pupal tissue infected with baculovirus. We demonstrated that modified folding and self-assembly occurs in the . ).
[0152] Example 6. Production of viral inoculum in infected T. niger pupae Spodoptera frugiperda (Sf21 and Sf9) cell lines were cultured in 10% heat-inactivated bovine serum Fetal serum (PAN Biotech GmbH) and gentamicin (50 μg / ml) (PAN Biotech GmbH) The cells were cultured at 27°C in TNMFH medium (PAN Biotech GmbH, Germany) containing 100% ethanol. The density and viability of the cells were determined by trypan blue staining. Cell viability was evaluated at various times post-infection. Calculations were based on the percentage of viable cells relative to the total number of cells at the time.
[0153] Sf9 cells cultured in suspension were diluted to 2 x 10 6 Spinner flasks at a cell density of 100 cells / ml The survival rate of the cells at the time of infection was 99. The multiplicity of infection (MOI) of Sf9 cells was 0.01 to 0.1. The cells were infected in vitro with recombinant baculovirus by IV infection. After 2 to 96 hours, the virus inoculum was centrifuged and then collected from the supernatant. was calculated by plaque-forming unit (pfu) assay and was 10 per ml. 7 Virus~ 10 8 Viral titers of the viruses were obtained.
[0154] 5×10 2 pfu~10 4 Infect T. niger pupae with viruses at doses ranging from p.f.u. After 3 to 7 days, the pupae were cultured in cell culture medium or in the presence of DTT and the protease inhibitor PMSF. Infectious viruses were collected by homogenizing pupae in a special PBS buffer containing The genet was centrifuged at 5,000 × g for 30 min to remove pupal debris. The supernatant containing the sucrose was filtered sequentially through 0.45 and 0.22 micron filters. The resulting virus preparation is preserved by mixing with glycerol and then frozen or The virus stock was titrated in 5th instar larvae of T. niger ( The larvae infection dose was titrated using the Karber method. The statistical significance of one infectious dose calculated in this way is ID This means that a population of 50 infected larvae would represent 50% infected individuals. For at least 96 hours, the eggs were incubated for 10 min to detect symptoms and follow their development to pupation. The typical virus titer was 10 / ml of virus preparation. 6 pfu~ 10 8 pfu. Furthermore, the viability of the baculovirus vector in cell culture was Baculovirus inocula can be obtained without the need for gene transfer into bacteria. The resulting bacmid can then be used to transfect pupae. 1 depicts the basic procedure for obtaining viral stocks in pupae depending on the cell line.
[0155] Example 7. Cell cultures and viruses Spodoptera frugiperda Sf21 or Sf9 cell lines in 6-well tissue culture plates (1×10 6 Cells / well) were incubated with 10% heat-inactivated fetal bovine serum (Pan in TNM-FH insect medium (Pan Biotech™, Germany) containing The cells were cultured at 27°C. The "Bac-to-Bac™" baculovirus expression system (US The AcMNPV recombinant baculovirus was obtained by the Invitrogen (trademark) Various TB(+) transfer vectors containing DNA regulatory elements were identified as pFastB. It was generated using the ac™-DUAL plasmid (Invitrogen™). The transfer vector was used to transfect the cells with Cellfectin™ (Invitrogen, USA). Sf21 cells were transfected with 100% PBS (en™). The resulting recombinant baculovirus was passaged twice in cells and subjected to plaque assay. The gene structure of the obtained TB(+) baculovirus expression cassette was The construct was transformed into a combination of gene regulatory elements involved in gene expression (polhAc-ie -01 / hr1p6.9p10, SEQ ID NO: 17, and the gene encoding the desired protein. The sequences of the genes are shown in Table 1 (e.g., SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 32 and SEQ ID NO: 33). The various expression cassettes are shown in Figs. 4, 7 and 10. The recombinant vaccinia used in the examples shown in Figs. 9, 11, 12, 13 and 14 produced a rovirus.
[0156] Example 8. Generation of cloning vectors The cloning vector is a restriction enzyme that creates the same overhangs for the vehicle and the foreign DNA. After enzymatic treatment, the foreign DNA fragments are synthesized by ligating the fragments together. A DNA containing a TB(+) baculovirus expression cassette into which a gene encoding the TB(+) vector can be inserted. The essential feature of a cloning vector is that it is a small piece of DNA that carries a foreign gene in a selected orientation. A functional origin of replication (ORI) for the actual transformed cells and growth in bacteria Synthetic markers that facilitate the insertion of selection markers, such as antibiotic resistance, allowing the selection of One important point is that the vector must contain a multiple coding sequence (MCS).
[0157] Example 9. Generation of donor vectors containing baculovirus expression cassettes of the invention The donor vector is a vaccinia vector into which a foreign gene has been cloned using appropriate restriction enzymes. from a cloning vector containing a rovirus expression cassette, e.g., pUC57 plasmid. The TB(+) baculovirus expression cassette used was prepared by ligating the following DNA sequence: (i) a promoter such as the polh promoter (e.g., SEQ ID NO: 10) The sequence Ac-ie- downstream of the motor sequence and upstream of the HSV TK polyadenylation signal 01 (e.g., SEQ ID NO: 1 to SEQ ID NO: 5), and (ii) at another locus, an enhancer sequence, e.g., (iii) a promoter - sequence, e.g. following the homologous region hr1 upstream of p6.9p10 (e.g. SEQ ID NO: 13), A multiple cloning site (MCS) for cloning the gene of interest, and a region below the MCS p10 polyadenylation signal of the baculovirus expression vector (Figure 4, Figure 7 and Figure 10). The set was subcloned into a transfer vector of a commercially available baculovirus production system. To facilitate sequencing (gene transposition, e.g., the "Bac-to-Bac™" system) system (Invitrogen™)-based or homologous recombination, e.g., "flashBAC ( Oxford Expression Technologies(trademark), Baculogold(trademark) )” (BD Biosciences (trademark)), “BacPAK6 (trademark)” (Clontech (trademark)), "Bac-N-Blue DNA™" (based on Invitrogen™), specific It is flanked by restriction sites (e.g., Bgl II and BstZ17l at the 5' end and Bgl II and Sgf I at the termini).
[0158] Coding foreign genes were cloned using the NcoI and SpeI restriction sites. The donor plasmid vector was generated by cloning the cDNA into the MCS of the target vector.
[0159] Example 10. Transfer vector containing the baculovirus expression cassette of the present invention Generate The transfer vector was digested with BstZ17 I and Xba I at the 5' flanking sites. The donor vector containing pF was digested with the same enzymes, and the transfer vector pF was digested with the same enzymes. AstBac™1 was generated by cloning into the As a result of the sequencing, the SV40 polyadenylation signal of the baculovirus expression cassette was transfected. The p10 polyadenylation signal from the transfer vector is exchanged. Alternatively, all elements of the expression cassette were contained in the pFastBac transfer vector. Rare, original commercially available transfer vector polh promoter and MCS Replace.
[0160] Example 11. Vaculophores of the invention using the "Bac-to-Bac™" system Generation of baculovirus expression vectors containing a virus expression cassette The modified transfer vector pFastBac™1 and TB(+) baculovirus The rus expression cassette was used to develop the "Bac-to-Bac™" baculovirus expression system. Recombinant baculoviruses were generated by using the following: A modified transfection vector containing a bacmid and helper plasmid The vector was used to transform the E. coli host strain DH10Bac™. Following gene transfer of the expression cassette, recombinant bacmids were generated. Recombinant TB(+) baculoviruses containing the expression cassette and various foreign coding genes The bacmid DNA was used to infect insect cells, e.g. For example, Sf21 cells were transfected with the bacmid. Trichoplusia ni (nettle looper moth) pupae aged 1 to 5 days were transfected. After 72 hours of transfection, cells or pupae were harvested and processed. The first recombinant baculovirus was generated. The recombinant baculoviruses could be further amplified and / or titered. Using the procedure, we have developed a system for the synthesis of other transfer vectors provided by commercially available BEVS. Recombinant baculovirus can be generated.
[0161] Example 12. Infection of insect pupae One- to five-day-old Trichoplusia ni pupae were used for all experiments. The standard weight of each pupa was approximately 200mg to 300mg, and they were cultured either manually or using specially designed The robot will then be used to measure the number of plaque-forming units (PFU) per dose selected. Add 1 μl to 10 μl of cell culture medium or recombinant baculovirus diluted in 1×PBS. The pupae were collected 72 to 168 hours after infection. The collected pupae were immediately frozen. The cells were then stored at -20°C or -80°C until processing for recombinant protein quantification. Total soluble non-denatured protein (TSNDP) from frozen T. niger pupae infected with tyrosine 2 (tyrosine 2) virus : Total soluble, non-denatured proteins) in the presence of extraction buffer for several minutes. Obtained by homogenization using a blender or homogenizer mixer.
[0162] Example 13. Downstream processing of insect pupae The frozen pupae were crushed in a homogenizer and diluted with reducing agent at concentrations of 1 mM to 25 mM, 0.01 The crude extract contained a mixture of detergents and protease inhibitors at concentrations of 0.5% to 2%. After the viscosity of the exudate was reduced by incubation with diatomaceous earth for a period of time, The extract was then centrifuged to remove insect debris and filtered to remove diatomaceous earth. Purify by tangential flow filtration using appropriate filters depending on the nature of the recombinant protein. Finally, a diafiltration process was carried out in the same tangential flow filtration device to obtain further The buffer was changed before chromatographic purification. FIG. 1 shows a general procedure for obtaining soluble recombinant protein extracts from stained pupae.
[0163] Item (I) of the present invention: 1. Autographa californica multicapsid nuclear polyhedrosis virus (AcMNPV) ) containing recombinant baculovirus and / or bacmid derived therefrom.
[0164] 2. The pupa according to item 1, wherein the pupa belongs to the order Lepidoptera.
[0165] 3. The above pupae are of the genera Trichoplusia, Lachyplusia, Spodoptera, Heliothis, and Man. Zucca, Helicoverpa, Ascara, or Samia, preferably Trichoprus A. ni species, Manzuca sexta species, Spodoptera frugiperda species, Spodoptera littoralis Rallis species, Ascarafa odorata species, Helicoverpa gii species, Heliothis villesii spp., Lachypurus spp., or Samia cynthia spp., or AcMNPV Any other pupae susceptible to infection with recombinant baculoviruses and / or bacmids derived from Item 1. A pupa according to Item 1.
[0166] 4. The baculovirus produces IgG that exceeds the endogenous levels obtained during baculovirus infection. Protein IE-1, protein IE-0 and / or protein thereof functioning as a transcriptional regulator The nucleic acid sequence that allows for expression of these fragments at levels above endogenous levels and the recombinant protein The recombinant protein is operably linked to any promoter suitable for driving expression of the protein. Item 4. The pupa according to any one of Items 1 to 3, further comprising the same region (hr).
[0167] 5. Function as a Transcriptional Regulator Above Endogenous Levels Obtained During Baculovirus Infection The endogenous proteins IE-1, IE-0 and / or their fragments Nucleic acid sequences that allow expression above the normal level and are used to drive the expression of recombinant proteins and a recombinant homology region (hr) operably linked to any suitable promoter. .
[0168] 6. The pupa according to item 5, wherein the pupa belongs to the order Lepidoptera.
[0169] 7. The above pupae are of the genera Trichoplusia, Lachyplusia, Spodoptera, Heliothis, and Man. Zucca, Helicoverpa, Ascara, or Samia, preferably Trichoprus A. ni species, Manzuca sexta species, Spodoptera frugiperda species, Spodoptera littoralis Rallis species, Ascarafa odorata species, Helicoverpa gii species, Heliothis villesii spp., Lachypurus spp., or Samia cynthia spp., or AcMNPV Any other pupae susceptible to infection with recombinant baculoviruses and / or bacmids derived from Item 7. The pupa according to Item 6.
[0170] 8. The pupa according to any one of items 1 to 7, wherein the pupa belongs to the species Trichoplusia ni.
[0171] 9. Expression of the above protein IE-1, protein IE-0 and / or fragments thereof The nucleic acid sequence enabling expression of (a) a nucleic acid comprising a nucleotide sequence shown in any one of SEQ ID NOs: 1 to 5; (b) a nucleotide sequence having at least 7 parts by weight, 0%, preferably at least 75%, more preferably at least 80%, more preferably At least 85%, more preferably at least 90%, and most preferably at least 9 It has 5% sequence identity with baculovirus and functions as a transcriptional regulator in recombinant baculovirus. a nucleic acid sequence encoding a protein to be obtained; (c) a coding sequence including an amino acid sequence shown in any one of SEQ ID NO:6 to SEQ ID NO:9; A nucleic acid sequence for coding the nucleic acid sequence, (d) a sequence that is at least 70% identical to any one of the amino acid sequences shown in SEQ ID NO:6 to SEQ ID NO:9; , preferably at least 75%, more preferably at least 80%, more preferably at least at least 85%, more preferably at least 90%, and most preferably at least 95% and can function as a transcriptional regulator in recombinant baculoviruses. A nucleic acid sequence encoding an amino acid sequence, Item 9. The pupa according to any one of items 4 to 8, selected from the group consisting of:
[0172] 10. The promoter driving the expression of the recombinant protein is (a) a compound represented by any one of SEQ ID NOs: 10 to 14, preferably SEQ ID NOs: 11 to 14 A nucleic acid comprising a nucleotide sequence as set forth in any of SEQ ID NOs: 13, and (b) a sequence capable of functioning as a promoter in a recombinant baculovirus; The sequence shown in any one of SEQ ID NO: 10 to SEQ ID NO: 14, preferably SEQ ID NO: 11 to SEQ ID NO: 1 3, which has at least 70%, preferably at least 7 5%, more preferably at least 80%, more preferably at least 85%, more preferably or at least 90%, and most preferably at least 95% sequence identity to array, Item 10. The pupa according to any one of items 4 to 9, wherein the nucleic acid is selected from the group consisting of nucleic acids comprising:
[0173] 11. The recombinant homologous region (hr) is the sequence (hr1) shown in SEQ ID NO: 21; Item 11. The pupa according to any one of items 4 to 10.
[0174] 12. A recombinant promoter, a sequence encoding a transcriptional regulator, and an enhancer region. The nucleic acid sequence comprising the combination is selected from the group consisting of SEQ ID NO: 15 to SEQ ID NO: 20. Item 12. The pupa according to any one of items 4 to 11.
[0175] 13. Any one of items 4 to 12, further comprising a nucleic acid sequence encoding a recombinant protein. The pupa described in.
[0176] 14. The recombinant protein is a subunit monomer vaccine, a subunit multimer vaccine, Cutin, virus-like particles, therapeutic proteins, antibodies, enzymes, cytokines, blood coagulation factors , anticoagulants, receptors, hormones, diagnostic protein reagents, and green fluorescent protein (GF Item 14. The pupa according to item 13, selected from the group consisting of:
[0177] 15. The recombinant protein is (a) a capsid derived from a porcine circovirus, preferably porcine circovirus type 2; Proteins (e.g., SEQ ID NO: 26), (b) foot-and-mouth disease virus VP1 protein, VP3 protein, or VP0 protein; (c) canine parvovirus VP1 and VP2 proteins, (d) porcine parvovirus VP1 protein and VP2 protein, (e) human norovirus (genogroup I or II) capsid protein, (f) calicivirus capsid protein; (g) L derived from a human papillomavirus, preferably human papillomavirus 16 1 protein, (h) hepatitis E protein E2, (i) Infectious bursal disease virus VP1 protein, VP2 protein and V P3 protein, (j) astrovirus ORF2-encoded protein; (k) influenza virus HA protein (e.g., SEQ ID NO: 30), NA protein protein and M1 protein, (l) Hepatitis B core and surface antigens; (m) human parvovirus VP1 and VP2 proteins, and (n) VP6 derived from rabbit calicivirus, preferably rabbit hemorrhagic disease virus 0 protein (e.g., SEQ ID NO:32 and SEQ ID NO:33), Item 15. The pupa according to item 14, wherein the virus-like particle protein is selected from the group consisting of:
[0178] 16. A method for producing a pupae as defined in any one of paragraphs 1 to 15 for the expression of a recombinant protein. use.
[0179] 17. The recombinant protein is a subunit monomer vaccine, a subunit multimer vaccine, Cutin, virus-like particles, therapeutic proteins, antibodies, enzymes, cytokines, blood coagulation factors , anticoagulants, receptors, hormones, diagnostic protein reagents, and green fluorescent protein (GF The use according to item 16, wherein the compound is selected from the group consisting of:
[0180] 18. The recombinant protein is (a) a capsid derived from a porcine circovirus, preferably porcine circovirus type 2; Proteins (e.g., SEQ ID NO: 26), (b) foot-and-mouth disease virus VP1 protein, VP3 protein, or VP0 protein; (c) canine parvovirus VP1 and VP2 proteins, (d) porcine parvovirus VP1 protein and VP2 protein, (e) human norovirus (genogroup I or II) capsid protein, (f) calicivirus capsid protein; (g) L derived from a human papillomavirus, preferably human papillomavirus 16 1 protein, (h) hepatitis E protein E2, (i) Infectious bursal disease virus VP1 protein, VP2 protein and V P3 protein, (j) astrovirus ORF2-encoded protein; (k) influenza virus HA protein (e.g., SEQ ID NO: 30), NA protein protein and M1 protein, (l) Hepatitis B core and surface antigens; (m) human parvovirus VP1 and VP2 proteins, and (n) VP6 derived from rabbit calicivirus, preferably rabbit hemorrhagic disease virus 0 protein (e.g., SEQ ID NO:32 and SEQ ID NO:33), The use according to item 17, wherein the virus-like particle protein is selected from the group consisting of:
[0181] 19. (a) preparing pupae; (b) Autographa californica multicapsid nuclear polyhedrosis virus (AcMN PV) into the pupae of step (a); (c) carrying out the steps (a) and (b) for a period of time sufficient to express at least one recombinant protein. b) incubating the inoculated pupae; (d) obtaining pupae containing at least one recombinant protein; (e) optionally harvesting the at least one recombinant protein; (f) optionally purifying at least one recombinant protein; 2. A method for producing at least one recombinant protein, comprising:
[0182] 20. The method according to item 19, wherein the pupa belongs to the order Lepidoptera.
[0183] 21. The above pupae are of the genera Trichoplusia, Lachyplusia, Spodoptera, Heliothis, and Ma Helicoverpa, Ascarafa, or Samia, preferably Trichople Scia ni sp., Manzuca sexta sp., Spodoptera frugiperda sp., Spodoptera li tolaris species, Ascarafa odorata species, Helicoverpa gii species, Heliothis villei sensu spp., Lachypurus nus spp., and Samia cynthia spp., or AcMNPV Any other pupae that are susceptible to infection with the recombinant baculovirus and / or bacmid derived from the 21. The method according to claim 20,
[0184] 22. The method according to claim 21, wherein the pupa belongs to the species Trichoplusia ni.
[0185] 23. The recombinant baculovirus is capable of expressing endogenous genes obtained during baculovirus infection. Proteins IE-1, IE-0 and IE-1 function as transcriptional regulators beyond the normal range. and / or fragments thereof, and nucleic acid sequences that allow for expression above endogenous levels. operably linked to any promoter suitable for driving expression of a recombinant protein. 23. The method according to any one of items 19 to 22, further comprising a recombinant homology region (hr).
[0186] 24. The above protein IE-1, protein IE-0 and / or fragments thereof The nucleic acid sequence enabling expression is (a) a nucleic acid comprising a nucleotide sequence shown in any one of SEQ ID NOs: 1 to 5; (b) a nucleotide sequence having at least 7 parts by weight, 0%, preferably at least 75%, more preferably at least 80%, more preferably At least 85%, more preferably at least 90%, and most preferably at least 9 It has 5% sequence identity with baculovirus and functions as a transcriptional regulator in recombinant baculovirus. a nucleic acid sequence encoding a protein to be obtained; (c) a coding sequence including an amino acid sequence shown in any one of SEQ ID NO:6 to SEQ ID NO:9; A nucleic acid sequence for coding the nucleic acid sequence, (d) a sequence that is at least 70% identical to any one of the amino acid sequences shown in SEQ ID NO:6 to SEQ ID NO:9; , preferably at least 75%, more preferably at least 80%, more preferably at least at least 85%, more preferably at least 90%, and most preferably at least 95% and can function as a transcriptional regulator in recombinant baculoviruses. A nucleic acid sequence encoding an amino acid sequence, 24. The method of claim 23, wherein the compound is selected from the group consisting of:
[0187] 25. The promoter driving the expression of the recombinant protein is (a) a compound represented by any one of SEQ ID NOs: 10 to 14, preferably SEQ ID NOs: 11 to 14 A nucleic acid comprising a nucleotide sequence as set forth in any of SEQ ID NOs: 13, and (b) a sequence capable of functioning as a promoter in a recombinant baculovirus; The sequence shown in any one of SEQ ID NO: 10 to SEQ ID NO: 14, preferably SEQ ID NO: 11 to SEQ ID NO: 1 3, which has at least 70%, preferably at least 7 5%, more preferably at least 80%, more preferably at least 85%, more preferably or at least 90%, and most preferably at least 95% sequence identity to array, 25. The method of claim 23 or 24, wherein the nucleic acid is selected from the group of nucleic acids comprising:
[0188] 26. The recombinant homologous region (hr) is the sequence (hr1) shown in SEQ ID NO: 21; 26. The method according to any one of items 23 to 25.
[0189] 27. A recombinant promoter, a sequence encoding a transcriptional regulator, and an enhancer region. The nucleic acid sequence comprising the combination is selected from the group consisting of SEQ ID NO: 15 to SEQ ID NO: 20. 27. The method according to any one of items 23 to 26.
[0190] 28. Any of items 19 to 27, wherein the pupa further comprises a nucleic acid sequence encoding a recombinant protein. The method according to any one of claims 1 to 5.
[0191] 29. The recombinant protein is a subunit monomer vaccine, a subunit multimer vaccine, Cutin, virus-like particles, therapeutic proteins, antibodies, enzymes, cytokines, blood coagulation factors , anticoagulants, receptors, hormones, diagnostic protein reagents, and green fluorescent protein (GF Item 29. The method according to item 28, wherein the compound is selected from the group consisting of:
[0192] 30. The recombinant protein is (a) a capsid derived from a porcine circovirus, preferably porcine circovirus type 2; Proteins (e.g., SEQ ID NO: 26), (b) foot-and-mouth disease virus VP1 protein, VP3 protein, or VP0 protein; (c) canine parvovirus VP1 and VP2 proteins, (d) porcine parvovirus VP1 protein and VP2 protein, (e) human norovirus (genogroup I or II) capsid protein, (f) calicivirus capsid protein; (g) L derived from a human papillomavirus, preferably human papillomavirus 16 1 protein, (h) hepatitis E protein E2, (i) Infectious bursal disease virus VP1 protein, VP2 protein and V P3 protein, (j) astrovirus ORF2-encoded protein; (k) influenza virus HA protein (e.g., SEQ ID NO: 30), NA protein protein and M1 protein, (l) Hepatitis B core and surface antigens; (m) human parvovirus VP1 and VP2 proteins, and (n) VP6 derived from rabbit calicivirus, preferably rabbit hemorrhagic disease virus 0 protein (e.g., SEQ ID NO:32 and SEQ ID NO:33), 30. The method of claim 29, wherein the virus-like particle protein is selected from the group consisting of:
[0193] 31. The method according to any one of items 19 to 30, wherein the pupa does not contain silk.
[0194] 32. The silk-free pupae are then soaked in a solution of a salt of hypochlorite, preferably sodium hypochlorite. 32. The method according to claim 31, wherein the silk of the cocoon containing the pupae of T. ni is obtained by dissolving the silk of the cocoon containing the pupae of T. ni in water. .
[0195] 33. Inoculation of the pupae with a recombinant baculovirus results in the pupa expressing the baculovirus. Item 33. The method according to any one of Items 19 to 32, wherein the method is carried out by injecting
[0196] 34. The pupae inoculated in step (b) are pupae defined in any one of items 1 to 15. The method according to any one of items 19 to 33.
[0197] 35. Inject 50PFU to 10 per pupa into the above pupae. 6 Inoculate baculovirus in an amount of PFU. The method according to any one of items 19 to 34,
[0198] 36. (a) providing pupae contained in cocoons; (b) treating the cocoons containing the pupae with a solution of a salt of hypochlorite, preferably sodium hypochlorite; and (c) obtaining silk-free, sterilized pupae; 1. A method for producing silk-free pupae belonging to the order Lepidoptera, comprising:
[0199] 37. The method according to claim 36, wherein the pupa does not belong to the species Bombyx mori.
[0200] 38. The method according to claim 36 or 37, wherein the pupa belongs to the species Trichoplusia ni.
[0201] 39. Any one of items 36 to 38, wherein the pupae are provided in a matrix (or array). The method described.
[0202] 40. (a) preparing pupae; (b) Autographa californica multicapsid nuclear polyhedrosis virus (AcMN PV) (step (a) transfecting pupae of (c) inoculating the culture medium of step (b) for a period of time sufficient to produce a recombinant baculovirus. Incubating the exposed pupae; (d) obtaining pupae containing the recombinant baculovirus; (e) optionally harvesting the recombinant baculovirus; (f) optionally purifying the recombinant baculovirus; A method for producing a recombinant baculovirus, comprising:
[0203] 41. The method according to claim 39, wherein the pupa is a pupa defined in any one of claims 36 to 39. .
[0204] 42. The method according to item 40 or 41, wherein the pupa belongs to the order Lepidoptera.
[0205] 43. The above pupae are of the genera Trichoplusia, Lachyplusia, Spodoptera, Heliothis, and Ma Helicoverpa, Ascarafa, or Samia, preferably Trichople Scia ni sp., Manzuca sexta sp., Spodoptera frugiperda sp., Spodoptera li tolaris species, Ascarafa odorata species, Helicoverpa gii species, Heliothis villei sensu, Lachypurus nucifera, or Samia cinthia, or AcMNP Any other pupae susceptible to infection with recombinant baculovirus and / or bacmid derived from V. Item 43. The method according to item 42, wherein
[0206] 44. The method according to claim 43, wherein the pupa belongs to the species Trichoplusia ni.
[0207] 45. Autographa californica multicapsid nuclear polyhedrosis virus (AcMNP) The bacmid suitable for producing a recombinant baculovirus derived from V) is Protein I functions as a transcriptional regulator above endogenous levels obtained during R. typhimurium infection. Expression of proteins IE-1, IE-0 and / or their fragments at levels higher than endogenous levels The nucleic acid sequence that allows expression of the recombinant protein and any suitable promoter that drives the expression of the recombinant protein. a recombinant homology region (hr) operably linked to a motor, 45. The method according to any one of items 40 to 44.
[0208] 46. The above protein IE-1, protein IE-0 and / or fragments thereof The nucleic acid sequence enabling expression is (a) a nucleic acid comprising a nucleotide sequence shown in any one of SEQ ID NOs: 1 to 5; (b) a nucleotide sequence having at least 7 parts by weight, 0%, preferably at least 75%, more preferably at least 80%, more preferably At least 85%, more preferably at least 90%, and most preferably at least 9 It has 5% sequence identity with baculovirus and functions as a transcriptional regulator in recombinant baculovirus. a nucleic acid sequence encoding a protein to be obtained; (c) a coding sequence including an amino acid sequence shown in any one of SEQ ID NO:6 to SEQ ID NO:9; A nucleic acid sequence for coding the nucleic acid sequence, (d) a sequence that is at least 70% identical to any one of the amino acid sequences shown in SEQ ID NO:6 to SEQ ID NO:9; , preferably at least 75%, more preferably at least 80%, more preferably at least at least 85%, more preferably at least 90%, and most preferably at least 95% and can function as a transcriptional regulator in recombinant baculoviruses. A nucleic acid sequence encoding an amino acid sequence, 46. The method of claim 45, wherein the compound is selected from the group consisting of:
[0209] 47. The promoter driving the expression of the recombinant protein is (a) a compound represented by any one of SEQ ID NOs: 10 to 14, preferably SEQ ID NOs: 11 to 14 A nucleic acid comprising a nucleotide sequence as set forth in any of SEQ ID NOs: 13, and (b) a sequence capable of functioning as a promoter in a recombinant baculovirus; The sequence shown in any one of SEQ ID NO: 10 to SEQ ID NO: 14, preferably SEQ ID NO: 11 to SEQ ID NO: 1 3, which has at least 70%, preferably at least 7 5%, more preferably at least 80%, more preferably at least 85%, more preferably or at least 90%, and most preferably at least 95% sequence identity to array, 47. The method of claim 45 or 46, wherein the nucleic acid is selected from the group of nucleic acids comprising:
[0210] 48. The recombinant homologous region (hr) is the sequence (hr1) shown in SEQ ID NO: 21; Item 48. The method according to any one of items 45 to 47.
[0211] 49. A recombinant promoter, a sequence encoding a transcriptional regulator, and an enhancer region. The nucleic acid sequence comprising the combination is selected from the group consisting of SEQ ID NO: 15 to SEQ ID NO: 20. Item 49. The method according to any one of items 45 to 48.
[0212] 50. The method according to any one of items 40 to 49, wherein the pupa is a silk-free pupa.
[0213] 51. The silk-free pupae are then soaked in a solution of a salt of hypochlorite, preferably sodium hypochlorite. 51. The method according to claim 50, wherein the T. ni pupae are obtained by lysing cocoons containing T. ni pupae in a broth.
[0214] 52. The transfected pupae of step (b) are transfected according to any one of paragraphs 5 to 15. 52. The method according to any one of items 40 to 51, wherein the pupa is a pupa that is cultured in a culture medium.
[0215] 53. The method according to any one of paragraphs 40 to 52, wherein the pupae are provided in a matrix.
[0216] 54. A precision pump, a mobile mechanical arm, and a Lepidoptera, preferably Trichoplusia, La Cyprusia, Spodoptera, Heliothis, Manduca, Helicoverpa, Ascala Genus Fa or genus Samia, more preferably Trichoplusia ni species, Manzuca sexta species, Spodoptera frugiperda species, Spodoptera litoralis species, Ascarafa odo Rata species, Helicoverpa zee species, Heliothis virescens species, Lachyprussia nucifera species, or Samia cynthia species, or recombinant baculovirus derived from AcMNPV. Suitable for injecting fluid into any other pupae susceptible to virus and / or bacmid infection ( and a movable (movable) needle.
[0217] 55. The device according to paragraph 54, wherein the pupae are provided in a matrix or array.
[0218] 56. The device defines the position of the needle and / or the distance from the needle to the pupa and and / or calculating the needle penetration distance into said pupae and / or the volume of liquid to inoculate said pupae; and / or determining the coordinates of said inoculation needle, and / or the volume and / or time of said inoculation of said pupae. Item 54 or further comprising a computer program for calculating the time between inoculations and / or between inoculations. 55. The apparatus according to claim 55.
[0219] 57. Update the computer program for calculating the inoculation time and / or the time between inoculations of the pupae. Item 57. The device according to item 56, comprising:
[0220] 58. Any of paragraphs 54 to 57, wherein the device further comprises a camera for determining the position of the needle. 13. The apparatus described in claim 1.
[0221] 59. The device according to item 54, wherein the pupa is a pupa defined in any one of items 1 to 15.
[0222] 60. The injected fluid contains a recombinant baculovirus or bacmid, 13. The device according to any one of claims 1 to 12.
[0223] 61. The device performs step (b) according to any one of paragraphs 19 and / or 40. The device according to any one of items 54 to 60, which is suitable for
[0224] 62. The fluid injected into the pupa is about 0.5 μL to about 10.0 μL, preferably about 5 μL. Item 54 to 61, the device according to any one of items 54 to 61,
[0225] 63. The needle penetrates the pupa at a distance of about 1 mm to about 5 mm, preferably about 3 mm. 54-62. An apparatus according to any one of claims 54 to 62.
[0226] 64. The fluid injected into the pupae preferably contains 50 PFU to 500 PFU per dose injected into each pupa. 10 6 Item 64. The device according to any one of items 54 to 63, comprising a baculovirus in an amount of PFU. .
[0227] Item (II) of the present invention: 1. Autographa californica multicapsid nuclear polyhedrosis virus (AcMNPV) ), preferably comprising a recombinant baculovirus and / or bacmid derived from The pupae are of the order Lepidoptera, preferably of the genus Trichoplusia, Lachypurusia, Spodoptera, Heteroptera, One of the following genera: Liotis, Manduca, Helicoverpa, Ascara, or Samia Layer preferably Trichoplusia ni species, Manduca sexta species, Spodoptera frugiperra da species, Spodoptera litoralis species, Ascarafa odorata species, Helicoverpa gii species , Heliothis virescens species, Lachypurus nus species, or Samia cynthia species or derived from AcMNPV. Any other pupa that is susceptible to staining is a pupa.
[0228] 2. The baculovirus produces IgG that exceeds the endogenous levels obtained during baculovirus infection. Protein IE-1, protein IE-0 and / or protein thereof functioning as a transcriptional regulator The nucleic acid sequence that allows for expression of these fragments at levels above endogenous levels and the recombinant protein The recombinant protein is operably linked to any promoter suitable for driving expression of the protein. The pupa according to item 1, further comprising the same region (hr).
[0229] 3. Function as a Transcriptional Regulator Above Endogenous Levels Obtained During Baculovirus Infection The endogenous proteins IE-1, IE-0 and / or their fragments Nucleic acid sequences that allow expression above the normal level and are used to drive the expression of recombinant proteins and a recombinant homology region (hr) operably linked to any suitable promoter. Preferably, the pupa is of the order Lepidoptera, preferably of the genus Trichoplusia, Lachyplusia, Spodoptera, Heliothis, Manduca, Helicoverpa, Ascarapha, or More preferably, the species is Trichoplusia ni, Manduca sexta, Spodoptera spp. Ptera frugiperda species, Spodoptera litoralis species, Ascara odorata species, Hexabra Lycopernicia spp., Heliothis virescens species, Lachypurus nucifera species, or Sa Recombinant baculoviruses belonging to the Mia synthia species or derived from AcMNPV and Pupae, which are / or any other pupae susceptible to infection with the bacmid.
[0230] 4. Expression of the above protein IE-1, protein IE-0 and / or fragments thereof The nucleic acid sequence enabling expression of (a) a nucleic acid comprising a nucleotide sequence shown in any one of SEQ ID NOs: 1 to 5; (b) a nucleotide sequence having at least 7 parts by weight, 0%, preferably at least 75%, more preferably at least 80%, more preferably At least 85%, more preferably at least 90%, and most preferably at least 9 It has 5% sequence identity with baculovirus and functions as a transcriptional regulator in recombinant baculovirus. a nucleic acid sequence encoding a protein to be obtained; (c) a coding sequence including an amino acid sequence shown in any one of SEQ ID NO:6 to SEQ ID NO:9; A nucleic acid sequence for coding the nucleic acid sequence, (d) a sequence that is at least 70% identical to any one of the amino acid sequences shown in SEQ ID NO:6 to SEQ ID NO:9; , preferably at least 75%, more preferably at least 80%, more preferably at least at least 85%, more preferably at least 90%, and most preferably at least 95% and can function as a transcriptional regulator in recombinant baculoviruses. A nucleic acid sequence encoding an amino acid sequence, is selected from the group consisting of A promoter driving expression of the recombinant protein, (a) a compound represented by any one of SEQ ID NOs: 10 to 14, preferably SEQ ID NOs: 11 to 14 A nucleic acid comprising a nucleotide sequence as set forth in any of SEQ ID NOs: 13, and (b) a sequence capable of functioning as a promoter in a recombinant baculovirus; The sequence shown in any one of SEQ ID NO: 10 to SEQ ID NO: 14, preferably SEQ ID NO: 11 to SEQ ID NO: 1 3, which has at least 70%, preferably at least 7 5%, more preferably at least 80%, more preferably at least 85%, more preferably or at least 90%, and most preferably at least 95% sequence identity to array, and selected from the group of nucleic acids comprising: Item 2 or Item 3, wherein the recombinant homologous region (hr) is the sequence (hr1) shown in SEQ ID NO: 21. Pupae according to 3.
[0231] 5. The recombinant promoter, a sequence encoding a transcriptional regulator, and an enhancer region. The nucleic acid sequence comprising the combination of is selected from the group consisting of SEQ ID NO: 15 to SEQ ID NO: 20 Item 5. The pupa according to any one of Items 2 to 4.
[0232] 6. The pupae are preferably a subunit monomer vaccine, a subunit multimer vaccine, Virus-like particles, therapeutic proteins, antibodies, enzymes, cytokines, blood clotting factors, anticoagulants From drugs, receptors, hormones, diagnostic protein reagents, and green fluorescent protein (GFP) Item 2 to 5, further comprising a nucleic acid sequence encoding a recombinant protein selected from the group consisting of: A pupa described in any one of claims 1 to 4.
[0233] 7. Use of pupae as defined in any one of items 1 to 6, preferably comprising a subunit single Monomeric vaccines, subunit multimeric vaccines, virus-like particles, therapeutic proteins, antibodies , enzymes, cytokines, blood clotting factors, anticoagulants, receptors, hormones, diagnostic proteins a recombinant protein selected from the group consisting of a reagent, and green fluorescent protein (GFP). Use of pupae for expression of
[0234] 8. (a) providing pupae, preferably silk-free pupae; (b) Autographa californica multicapsid nuclear polyhedrosis virus (AcMN PV) into the pupae of step (a); (c) carrying out the steps (a) and (b) for a period of time sufficient to express at least one recombinant protein. b) incubating the inoculated pupae; (d) obtaining pupae containing at least one recombinant protein; (e) optionally harvesting the at least one recombinant protein; (f) optionally purifying at least one recombinant protein; Including, Preferably, the pupa is from the order Lepidoptera, preferably from the genus Trichoplusia, Lachypurusia, Spodoptera, Thera, Heliothis, Manduca, Helicoverpa, Ascarapha, or Samia More preferably, Trichoplusia ni species, Manduca sexta species, Spodoptera Frugiperda species, Spodoptera litoralis species, Ascarapha odorata species, Helicobacter Pa ji species, Heliothis virescens species, Lachypurus nu species, or Samia schidigera Recombinant baculoviruses and / or baculoviruses belonging to the species Bacillus subtilis or derived from AcMNPV. Any other pupae that are susceptible to infection with cumids and produce at least one recombinant protein How to do it.
[0235] 9. The recombinant baculovirus expresses the endogenous level of baculovirus obtained during infection. The proteins IE-1, IE-0 and IE-11, which function as transcriptional regulators across the or a fragment thereof, and a nucleic acid sequence that allows for expression above endogenous levels. The construct is operably linked to any promoter suitable for driving the expression of the protein. and a recombinant homology region (hr), preferably obtained during baculovirus infection. The above proteins IE-1 and protein I function as transcriptional regulators at levels higher than the inducible level. The above nucleic acid allows for expression of E-0 and / or fragments thereof above endogenous levels. The nucleic acid sequence may be modified with any promoter suitable for driving the expression of a recombinant protein. The operably linked recombinant homology region (hr) is as defined in claim 4. The method according to item 8, wherein
[0236] 10. A recombinant promoter, a sequence encoding a transcriptional regulator, and an enhancer region. The nucleic acid sequence comprising the combination is selected from the group consisting of SEQ ID NO: 15 to SEQ ID NO: 20. Item 12. The method according to item 11.
[0237] 11. The pupae are preferably a subunit monomer vaccine, a subunit multimer vaccine, Antibodies, enzymes, cytokines, blood coagulation factors, Coagulants, receptors, hormones, diagnostic protein reagents, and green fluorescent protein (GFP) The method according to claim 8, further comprising a nucleic acid sequence encoding a recombinant protein selected from the group consisting of: 12. The method of any one of claims 10 to 11.
[0238] 12. (a) providing pupae contained in silk cocoons; (b) soaking the silk cocoons containing the pupae in a solution of a salt of hypochlorite, preferably sodium hypochlorite; A step of processing; (c) obtaining silk-free, sterilized pupae; 23. A method for producing silk-free pupae belonging to the order Lepidoptera, preferably T. ni species, comprising:
[0239] 13. (a) preferably Lepidoptera, preferably Trichoplusia, Lachyplusia, Spodoptera Genus La, Heliothis, Manduca, Helicoverpa, Ascarapha, or Samia More preferably, Trichoplusia ni species, Manduca sexta species, Spodoptera flavum species, Rugiperda species, Spodoptera litoralis species, Ascarapha odorata species, Helicoverpa Heliothis zee, Heliothis virescens, Lachypurus nu, or Samia sinensis pupae belonging to the S. spp., or recombinant baculovirus and / or baculovirus derived from AcMNPV. Providing any other pupae susceptible to infection with silkmids, preferably silk-free pupae; (b) Autographa californica multicapsid nuclear polyhedrosis virus (AcMN The pupae of step (a) were cultured with a bacmid suitable for the production of recombinant baculovirus derived from P. cerevisiae (PV). transfecting; (c) inoculating the culture medium of step (b) for a period of time sufficient to produce a recombinant baculovirus. Incubating the exposed pupae; (d) obtaining pupae containing the recombinant baculovirus; (e) optionally harvesting the recombinant baculovirus; (f) optionally purifying the recombinant baculovirus; A method for producing a recombinant baculovirus, comprising:
[0240] 14. Autographa californica multicapsid nuclear polyhedrosis virus (AcMNP) The bacmid suitable for producing a recombinant baculovirus derived from V) is Proteins that function as transcriptional regulators above endogenous levels obtained during rovirus infection The present invention relates to a method for the production of IE-1, IE-0 and / or their fragments, comprising the steps of: The nucleic acid sequence capable of expressing the recombinant protein can also be used as a vector. and a recombinant homology region (hr) operably linked to the promoter of and preferably transfected above endogenous levels obtained during baculovirus infection. The above-mentioned protein IE-1, protein IE-0 and / or protein thereof functioning as a transcription regulator The nucleic acid sequences described above allow for expression of these fragments at levels greater than endogenous, as well as recombinant The vector is operably linked to any promoter suitable for driving expression of the protein. 14. The recombinant homologous region (hr) according to claim 13, wherein the recombinant homologous region (hr) is as defined in claim 4. How to.
[0241] 15. A recombinant promoter, a sequence encoding a transcriptional regulator, and an enhancer region. The nucleic acid sequence comprising the combination is selected from the group consisting of SEQ ID NO: 15 to SEQ ID NO: 20. Item 15. The method according to item 14.
[0242] 16. A precision pump, a mobile mechanical arm, and a Lepidoptera, preferably Trichoplusia, La Cyprusia, Spodoptera, Heliothis, Manduca, Helicoverpa, Ascala or Samia genus, more preferably Trichoplusia ni species, Manzuca sec sta species, Spodoptera frugiperda species, Spodoptera litoralis species, Ascarafa odorata species, Helicoverpa zee species, Heliothis virescens species, Lachyprussia nucifera or Samia cynthia species, or recombinant bacillovirus derived from AcMNPV. Suitable for injecting fluid into any other pupae susceptible to infection with urovirus and / or bacmid. and a movable needle, preferably wherein the pupae are provided in a matrix or array. Place.
[0243] 17. The device defines the position of the needle and / or the distance from the needle to the pupa and and / or the needle penetration distance into the pupa and / or the liquid (preferably recombinant) to be inoculated into the pupa. and a computer program for calculating the volume of the baculovirus or bacmid. The device is preferably adapted to determine, for example, the coordinates of the inoculation needle and / or the pupa. A computer program for calculating the volume and / or time of said inoculations and / or the time between inoculations. Item 17. The apparatus of item 16, further comprising a ram.
Claims
1. 1. A method for producing at least one recombinant protein, the method comprising: (a) providing pupae belonging to Trichoplusia ni species contained in silk cocoons; (b) removing the silk cocoon of each pupa; (c) obtaining silk-free, externally sterilized pupae; (d) injecting a recombinant baculovirus derived from Autographa californica multicapsid nuclear polyhedrosis virus (AcMNPV) and comprising a nucleic acid sequence encoding said recombinant protein into the pupae of step (c); however, (i) the pupae are placed in a matrix or array of small holes, each with a lid having a hole in its center, where the holes in the lid are smaller than the pupae such that only a needle can pass through the hole; and (ii) said injection is carried out by means of a device comprising a precision pump, a mobile mechanical arm and a needle suitable for injecting fluids into the interior of the pupa; however, - the device automatically places at least one needle into at least one of the pores containing the pupae so that the needle passes through a hole in the lid to access the pupae; and - the needle pierces the pupa and administers the solution containing the recombinant baculovirus into the body of the pupa; - the needle is removed from the pupa and the hole, leaving the pupa in the hole; (e) incubating the inoculated pupae of step (d) for a period of time sufficient to allow expression of at least one recombinant protein; (f) obtaining pupae containing at least one recombinant protein.
2. 2. The method of claim 1, wherein the silk cocoons are removed by dissolving them in a solution of a salt of hypochlorite.
3. The baculovirus comprises a nucleic acid sequence that allows expression of the protein IE-1, the protein IE-0 and / or fragments thereof, which function as a transcription regulator, above the endogenous level obtained during baculovirus infection, and a recombinant homology region (hr) operably linked to any promoter suitable for driving the expression of the recombinant protein, said nucleic acid sequence allowing the expression of said protein IE-1, said protein IE-0 and / or their fragments, (1) A nucleic acid sequence comprising a nucleotide sequence shown in any one of SEQ ID NOs: 1 to 5; (2) A nucleic acid sequence having at least 90% sequence identity with the nucleotide sequence shown in any one of SEQ ID NOs: 1 to 5, and encoding a protein capable of functioning as a transcriptional regulator in a recombinant baculovirus; (3) A nucleic acid sequence encoding an amino acid sequence comprising any one of the amino acid sequences set forth in SEQ ID NO:6 to SEQ ID NO:9, and (4) A nucleic acid sequence encoding an amino acid sequence having at least 90% sequence similarity to any of the amino acid sequences shown in SEQ ID NOs: 6 to 9 and capable of functioning as a transcriptional regulator in a recombinant baculovirus; The method of claim 1 or 2, wherein the compound is selected from the group consisting of:
4. The method according to claim 3, wherein the nucleic acid sequence comprising a combination of a recombinant promoter, a sequence encoding a transcriptional regulator and an enhancer region is selected from the group comprising SEQ ID NO: 15 to SEQ ID NO:
20.
5. moreover, (g) harvesting the recombinant baculovirus. The method according to any one of claims 1 to 4, comprising:
6. moreover, The method of claim 5, further comprising the step of (h) purifying the recombinant baculovirus.
Citation Information
Patent Citations
Inoculation to silkworm
JP1997051742A
Production of useful protein and silkworm used therefor
JP1997215499A
Baculoviral DNA elements for recombinant protein expression in host cells
JP2015519068A
Insect Infection Method for Production of Proteins
US20110314562A1
Recombinant DNA elements for the expression of recombinant proteins in a host cell
WO2012168492A2
